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ABSTRACT 
 In the UK, multiple sclerosis (MS) is the leading cause of non-
traumatic disability in young adults.  MS most commonly presents in a 
relapsing-remitting form (RRMS); however, over time, a progressive, 
neurodegenerative pathology dominates, and the disease enters a 
secondary progressive phase.  Approximately, 10-15% of MS cases are 
primary progressive, some with superimposed relapses.  During RRMS 
an underlying autoimmune pathology presides which leads to nerve 
damage through inflammatory processes.  Therapeutic modulation of 
these inflammatory processes is beneficial in reducing relapses and 
increasing the periods between them.  A key approach is to induce a 
switch in immune system reactivity from a proinflammatory (T helper1) 
to a less inflammatory (T helper2) profile.  Immune system regulation is 
faulty in MS and reconstitution of regulatory T and B cell activity is a 
goal of effective intervention strategies.  There is evidence that 
Intestinal parasite (helminth) infection is protective for MS as it induces 
a T helper2 profile and promotes regulatory cell activity.  Deliberate, 
controlled helminth infection may be a useful therapeutic intervention. 
 In 2012, the Nottingham University Hospitals Multiple Sclerosis 
Clinic commenced the Worms for immune regulation of multiple 
sclerosis (WIRMS) study (NCT 01470521), which was a randomized, 
double-blinded, placebo controlled study of hookworm treatment of 
multiple sclerosis.  A total of 72 patients were enrolled, 36 were infected 
with 25 larvae of Necator americanus and 36 were given placebo.  At 
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the time of commencement, this was the largest study so far performed 
to assess the efficacy and safety of helminth therapy.  Subsequently, 
concerns that helminth therapy might induce Epstein-Barr virus (EBV) 
reactivation have been raised and a key objective of the study 
presented in this thesis was to assess whether EBV reactivation is a 
complication of helminth therapy.  Because a unique collection of 
serially collected samples was available together with relevant clinical 
information it has proven possible to investigate the time course of 
infection of EBV and other selected human herpesviruses 
(cytomegalovirus and varicella zoster virus) in helminth treated and 
placebo controlled patients. 
 Markers of EBV infection (early antigen IgG – EBV EA IgG, virus 
capsid antigen IgG and IgM – EBV VCA IgG and IgM, nuclear antigen-1 
IgG – EBNA-1 IgG), cytomegalovirus infection (CMV IgG) and varicella- 
zoster virus infection (VZV IgG) were measured using commercially 
available enzyme-linked immunoassays (ELISAs).  Samples from 51 
patients (26 helminth infected and 25 placebo controlled) were 
available for testing and pre-treatment status was measured together 
with levels during the nine months of helminth infection and post 
infection/placebo status three months after the cessation of treatment.  
There was no evidence of treatment related herpesvirus reactivation in 
any of the patients sampled.  Pre-treatment a total of 8 (30.7%) 
helminth treated patients were EBV EA IgG positive compared to 10 
(40.0%) placebo controlled patients.  The difference in the EBV EA IgG 
sero-positivity between the two groups was not significant and a state of 
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constant reactivation was maintained throughout the study period.  All 
patients (n = 51) were EBV VCA IgG and EBNA-1 IgG positive and 
antibody levels were stable throughout the study.  One helminth treated 
patient was EBV VCA IgM positive and one placebo-controlled patient 
was EBV VCA IgM positive and in both cases, the pre-treatment serum 
samples were EBV VCA IgM positive.  A total of 13 (50%) helminth 
treated patients and 4 (16.0%) placebo control patients were positive 
for CMV IgG.  The difference in the CMV IgG sero-positivity between 
the two groups was significant.  Generally, the CMV IgG levels were 
stable throughout the study period.  All patients were VZV IgG positive 
and VZV IgG levels were constant over the study period in all but one 
case. 
 In conclusion, there was no evidence of EBV reactivation, or 
reactivation of other human herpesviruses, at the therapeutic dose of N. 
americanus used.  The number of N. americanus larvae used to infect 
patients may prove critical as higher doses may prove deleterious to the 
patient and lower doses may fail to generate an adequate immune 
response.  Generally, antibody levels of all IgG markers were stable 
throughout the study period.  There was a significant mismatch of CMV 
seropositivity between the helminth treated and placebo control groups 
and the reasons for this sero-discordance are difficult to explain, 
particularly as patient recruitment was randomized.  Cytomegalovirus 
serostatus may influence host immune responses and so prejudice the 
key principle that “like” is being compared with “like” apart from the 
treatment given.  It would be most interesting to determine if other 
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“randomized” clinical trials show CMV sero-discordances at the 
recruitment stage.  Future clinical trials assessing the 
immunomodulatory effects of helminth infection may need to take 
account of patient CMV sero-status at the recruitment stage if the 
findings of this study are replicated.  Finally, for this study the bulk of 
patient clinical data remains to be made available at the time of writing 
of this thesis, so any conclusions put forward should be viewed as 
preliminary. 
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  1 
INTRODUCTION 
1.1 Clinical presentation and diagnosis of multiple sclerosis 
1.1.1 Historical 
Descriptions of afflictions resembling multiple sclerosis can be traced 
back to the late 14th Century; however, it was not until the first half of 
the 19th century that convincing accounts of the disease and the 
presence of plaques in the nervous system became available (1).  
Reading the personal diary of Augustus d’Este (1794-1848) a disease 
is described commencing with attacks of visual disturbances followed 
by episodes of leg weakness and gait disturbance culminating with 
increasing spasticity (2).  It was not until the second half of the 19th 
century that physicians could ascribe this set of signs and symptoms as 
multiple sclerosis. Following their appointments as “chefs de service” at 
La Salpȇtrière, Paris in late 1861 (3), Jean-Martin Charcot (1825-1893) 
and Alfred Vulpian (1826-1887) first described multiple sclerosis in a 
clinico-pathological context. In a series of lectures and case 
presentations given between 1865-1868, their descriptions of “la 
sclérose en plaques” characterized multiple sclerosis as a distinct 
clinical entity enabling others to identify the same disease in their 
patients.  Charcot’s triad of intention tremor, nystagmus and scanning 
speech became widely adopted for diagnosis during life; however, it 
was only at autopsy that a more definitive diagnosis could be made.  
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In England, cases of “insular sclerosis” were first fully described 
during the period 1873-1875 (4).  Over the next 70 years a variety of 
proposals were made as to the causation and distribution of the 
disease. For example, there were reports that multiple sclerosis was 
relatively common; others stated it to be relatively rare. There were 
reports of an association of the disease with higher latitudes; and there 
were reports that multiple sclerosis was more frequent in females, 
which were contradicted by other reports that it was more frequent in 
males.  A review by Tracy J Putnam (5) assessed the state of medical 
knowledge by the early 1940s.  There was little agreement amongst 
neuropathologists as to the aetiology of demyelinating diseases (post-
infectious and disseminated encephalomyelitis, Schilder’s disease, 
diffuse sclerosis, neuromyelitis optica and acute transverse myelitis) 
although all had the same underlying histopathology, differences being 
due to the location and intensity of lesions.  An important diagnostic 
point was to show evidence of lesions scattered in time and space, and 
examination of spinal fluid greatly helped with diagnosis.  Finally, the 
local incidence of multiple sclerosis showed an association with latitude, 
the disease being relatively more common in the Baltic countries, 
Scotland, and the North Atlantic seaboard compared to southern 
Europe, southern states of the USA and countries such as China. 
An accurate diagnosis of multiple sclerosis is important not only 
in the clinical context, but is essential for the purposes of clinical trials of 
treatments and the understanding of the aetiology of disease.  The 
specificity of a clinical diagnosis of multiple sclerosis was initially shown 
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to be highly variable.  For instance, during the 1960s Charles Poser 
undertook a study (6) in which detailed clinical summaries of 25 
autopsied cases of multiple sclerosis were sent to 190 neurologists in 
52 countries.  They were asked to classify the cases as probable, 
possible, or unlikely according to their own criteria, and 108 responses 
were received from 33 different countries.   Following analysis, the 
variability in the accuracy of diagnosis ranged from 2.8% to 91.7% for 
cases of “pure” multiple sclerosis.  By the end of the 20th Century 
several clinical diagnostic algorithms for diagnosis of multiple sclerosis 
had been proposed; however, despite the availability of laboratory 
techniques such as oligoclonal banding and imaging techniques such 
as magnetic resonance imaging (MRI) the diagnosis of multiple 
sclerosis still presented challenges and universally accepted criteria 
were lacking (7, 8). 
1.1.2 Multiple sclerosis diagnosis in the 21st Century 
Magnetic resonance imaging now plays a pivotal role in the diagnosis 
of multiple sclerosis. It is used to confirm or reject the clinical diagnosis, 
for monitoring of disease activity, and as a key outcome measure in 
clinical trials (9).  In 2001, an international panel recommended 
diagnostic criteria (often referred to as the “McDonald criteria”) for 
multiple sclerosis, which for the first-time integrated specific MRI 
evidence with clinical and other paraclinical diagnostic methods for 
lesion dissemination in time and space (10).  Particular strengths of the 
International Panel MRI recommendations were that they enabled 
earlier diagnosis, therefore reducing uncertainty and anxiety for many 
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patients while at the same time the likelihood of false-positive diagnosis 
was reduced (11).  A review of the application of the new McDonald 
diagnostic criteria in patients presenting with clinically isolated 
syndromes (CIS) suggestive of multiple sclerosis showed that within a 
year there was a 28% increase in confirmed diagnoses of multiple 
sclerosis compared with previous diagnostic criteria (12).  The 
McDonald criteria were refined further in 2005 (13) and 2010 with 
progressive improvements of sensitivity to 72% without corresponding 
reductions in specificity, which ranged between 87% - 91% (14). 
 The International Panel on diagnosis of multiple sclerosis met for 
a third time during May 2010 in Dublin, Ireland (15).  Aims of the 
meeting were to review the 2005 McDonald criteria in the light of new 
research findings, examine requirements for showing dissemination in 
time and space and focus on application to paediatric, Asian and Latin 
American populations.  In England, current National Institute for Health 
and Care Excellence (NICE) guidelines (16) on diagnosing multiple 
sclerosis are based on the McDonald criteria.  They stipulate that the 
diagnosis of multiple sclerosis should not be made on the basis of the 
results of magnetic resonance imaging alone and that clinical history 
and presentations together with risk stratification should be given due 
consideration. 
 The preceding sections show that diagnosis of multiple sclerosis 
and monitoring of clinical course including the identification of relapses 
is primarily a clinical exercise aided by the availability, in particular, of 
suitable imaging data.  When considering the impact of treatment on 
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the course of multiple sclerosis it is vital that consultant neurologists 
highly experienced in this field of medicine undertake review of clinical 
effect.  Despite the progress that has been made, rates of misdiagnosis 
of multiple sclerosis may be as high as 10% (17).  There is no 
laboratory test available for the diagnosis of multiple sclerosis although 
CSF examination (total IgG and oligoclonal binding) can be deemed 
useful, and detection of aquaporin 4 antibodies has proved most useful 
for the differential diagnosis of neuromyelitis optica spectrum disorder 
(18).  This section shows that for the purposes of understanding the 
aetiology of multiple sclerosis and assessing the impact of disease 
modifying interventions careful patient recruitment and monitoring by 
highly experienced physicians are required. 
Multiple sclerosis is a central nervous system disease in which 
the myelin nerve sheath is progressively destroyed (demyelination) with 
associated axonal damage/loss and nerve cell death (19).  The 
destruction is immune-mediated taking place as part of an inflammatory 
process (20).  The disease initially presents in one of two forms; 
relapsing-remitting multiple sclerosis (RRMS) which is seen in 
approximately 85% of cases (21), or primary progressive multiple 
sclerosis (PPMS).  In RRMS, remissions due to myelin repair, 
resolution of inflammation, and neural plasticity, become less frequent 
over time and the disease assumes a secondary progressive (SPMS) 
course (22). 
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1.2 Is multiple sclerosis an autoimmune (or infectious) 
disease? 
1.2.1 An overview of the epidemiology and genetics of multiple 
sclerosis 
 Multiple sclerosis is the leading cause of non-traumatic 
neurological disability in young adults in the UK and Europe although 
national level data is limited, and the application of differing diagnostic 
criteria combined with the differing sensitivities and specificities of such 
criteria (see 1.1.2) hamper spatial and temporal comparisons (23).  In 
the UK, the number of new cases over time (incidence) and the burden 
of disease within populations over time (prevalence) appears to be 
increasing (24, 25).  Recently, it has been estimated that there were 
126,669 (203.4/100,000) people living with multiple sclerosis in the UK 
and that this number represented a year on year increase of 
approximately 2.4% for the period 1990 – 2010 (26).  Differences in the 
prevalence of multiple sclerosis in UK regions have been observed; for 
example, the rates of disease are significantly higher in Scotland (27, 
28) compared to regions of England (29, 30). 
From a global perspective, an estimated 2.3 million people are 
believed to have multiple sclerosis (31) with the highest prevalence in 
the USA and Europe and the lowest prevalence in Africa, Asia, and 
South America. For many of the purportedly low-prevalence regions the 
quality of the epidemiological data is limited (32) and prevalence rates 
may be significantly higher than initially predicted (33, 34).  Multiple 
sclerosis is generally recorded two to three times more frequently in 
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females (35) and increases of prevalence in this population have been 
observed to be a driver for the increased overall prevalence of multiple 
sclerosis (36, 37).  Several studies (35, 38) have noted that the marked 
female sex-linkage is apparent for relapsing-remitting multiple sclerosis 
and that it appears to be absent or much reduced in primary 
progressive disease. 
 There is increasing evidence that genetic, environmental, and 
socio-economic factors have a role in the development of multiple 
sclerosis (39, 40).  Possible explanations for the spatial distributions of 
multiple sclerosis include intrinsic population genetic susceptibilities 
(41), levels of vitamin D (42), lack of exposure to UV radiation (43), and 
adoption of “Westernized” lifestyles (44).  Further discussion of these 
factors is beyond the scope of this thesis; however, infections represent 
another major risk factor and will now be discussed.   
1.2.2 Does multiple sclerosis have an infectious cause? 
 Multiple sclerosis is generally recognized as an autoimmune 
mediated disease in which demyelination and axonal death is immune 
mediated (45); however, there is increasing evidence of ongoing 
neurodegenerative processes even in the early stages (46).  
Autoimmune diseases typically show an interaction of genetic and 
environmental factors to varying extents (47).  However, an alternative 
view has been proposed (48, 49) suggesting that multiple sclerosis is 
an infectious process.  Several lines of evidence have been quoted in 
support of this view including the discordance of multiple sclerosis in 
identical twins, altered humoral and cell mediated responses, migration 
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studies and recurrent outbreaks of disease.  Familial aggregation 
studies (50) have shown an increased recurrence risk of multiple 
sclerosis in monozygotic twins (25-30%), and a reduced recurrence risk 
is apparent in half siblings (1.32%) compared to full siblings (3.46%) 
against an estimated general population and adopted sibling recurrence 
risk of 0.2%.  Most monozygotic twins are discordant and although 
many allelic associations have been identified in genome analysis 
studies (51) there still remains a lack of a definitive genetic marker for 
multiple sclerosis.  Oligoclonal banding is seen in many cases of 
multiple sclerosis with the conclusion that intrathecally-produced 
immunoglobulins contribute to the disease process (52) and it has been 
suggested that the IgG manifest in such bands is produced in response 
to the causative agent of multiple sclerosis in a similar manner to 
specific IgG produced intrathecally during infectious encephalitides 
(53).  In general (54), migrant studies, despite their inherent limitations, 
have shown that population groups living in areas of higher multiple 
sclerosis risk see a reduction in risk of multiple sclerosis following 
migration to areas of lesser multiple sclerosis risk, and there is limited 
evidence that moves from low risk areas to higher risk areas result in an 
increased risk of multiple sclerosis.  Furthermore, it appears that this 
phenomenon is most prominent in individuals who migrate during the 
first two decades of life.  Finally, compelling epidemiological evidence, 
which frequently has been given in support of an infectious cause of 
multiple sclerosis, is a series of outbreaks of multiple sclerosis that 
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occurred in the Faroe Islands following an occupation by British troops 
during the 1940s (48, 55). 
 Several microbial agents have been proposed, particularly those 
responsible for childhood infection, as having the potential for playing a 
significant role in the development of multiple sclerosis; however, 
definitive evidence remains to be provided (56).  Potentially, significant 
microbial associations have been reported for Epstein Barr virus (57), 
Chlamydia pneumoniae (58), and human endogenous retroviruses (59).  
The role of human herpes viruses in multiple sclerosis is reviewed in 
section 1.4.   
1.2.3 The Hygiene Hypothesis 
 Autoimmune diseases are a group of diseases characterized by 
a loss of immunological tolerance to self-antigens.  In most cases, the 
development of autoimmune disease is a product of a complex 
interaction between intrinsic susceptibility (or protection) mediated at 
the genetic level and external or environmental factors (60, 61).  The 
spatial distribution of autoimmune diseases has been shown to be 
highly variable (62) and temporal trends are disease specific; for 
example, childhood type 1 diabetes has increased worldwide during the 
20th Century (63), although this trend is not apparent for rheumatoid 
arthritis (64).  The Hygiene hypothesis was initially proposed to explain 
the increasing incidence of allergic diseases and was subsequently 
shown to be equally applicable in accounting for the increasing 
incidence of autoimmune diseases (65). 
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 In the first instance, the Hygiene Hypothesis made the 
proposition that reduced exposure to infections during childhood led to 
an increase in allergic diseases (66).  Subsequently, spatial variations 
in allergic and autoimmune diseases were shown to be related to 
socioeconomic conditions (67) so that their frequency was increased in 
populations with high economic status (eg. Northern Europe) and 
decreased in populations with lower socioeconomic status (eg. 
Southern Europe).  Animal studies, epidemiological studies, and 
migration studies have both proven useful in providing additional 
evidence in support of the Hygiene Hypothesis.  Studies (68) of non-
obese diabetic mice have shown that housing conditions and exposure 
to virus infections are key determinants in the development of type 1 
diabetes.  Finland, an affluent country, has the highest incidence of 
type 1 diabetes in the World whereas in the neighbouring, less affluent, 
Russian Karelia the incidence of type 1 diabetes is significantly lower, 
and this is believed to be linked to the differing microbial challenges 
prevalent in each country (69).  Finally, a review (70) of multiple 
sclerosis cases in Gothenburg, Sweden showed that an Iranian 
subpopulation, which migrated mainly during the 1980s and 1990s, 
manifested an increased risk of multiple sclerosis compared of their 
birthplace, approximating to that of the indigenous Swedish population. 
1.2.4 The impact of parasite infection on multiple sclerosis and the 
Hygiene Hypothesis 
 A tenuous correlation has been observed (71) between the 
decline of certain bacterial (eg. rheumatic fever and tuberculosis) and 
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virus (eg. measles, hepatitis A) infections and the rising incidence of 
certain autoimmune diseases (eg. multiple sclerosis, type 1 diabetes).  
Low levels of allergic and autoimmune diseases have been associated 
with countries experiencing high levels of helminthic infestations and 
common factors are inadequate sanitation, poor diet, and low 
socioeconomic status (72, 73).  Following anti-helminthic eradication 
programmes increased population incidences of allergic and 
autoimmune diseases have been reported (74).  Additionally, allergic 
reactions have been shown to recur in individuals following successful 
anti-helminthic eradication treatment (75).  Immunologically, helminth 
infestation generates a complex immune response involving both 
adaptive and innate pathways.  A broadly anti-inflammatory TH2 
response is generated characterized by elevated levels of associated 
cytokines (eg. IL-4, IL-5, IL-10, IL-13, TGF-β), suppression of TH1 
inflammatory cytokines (eg. IFN-γ) and modified regulatory B and T cell 
activity (76, 77). 
In the context of multiple sclerosis, there is considerable 
evidence (78) implicating the increasing incidence of multiple sclerosis 
to be inversely correlated with a decreasing prevalence of helminth 
infestation.  Epidemiological studies (79) and studies of helminth 
infection in animal models of multiple sclerosis (80) have generated 
evidence supporting the suggestion of an interaction between helminth 
infestation and multiple sclerosis.  Furthermore, human studies have 
shown that helminth infection can immunomodulate the relapsing and 
remitting form of disease (81) through increased production of IL-10 
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and TGF-β with induction of CD25+CD4+FoxP3+T cells and that this 
effect is reversed following helminth eradication (82).   
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1.3 Treatment strategies for multiple sclerosis 
1.3.1 The early days of treatment 
“It would be nice if a physician from London, one of these days, 
were to gallop up hotspur, tether his horse to the gait post and 
dash in waving a reprieve –the discovery of a cure!” 
Excerpt from “The Journal of a disappointed Man” by B. F. Cummings 
(1889-1919) who wrote under the literary name of W. N. P. Barbellion.  
Source T. Jock Murray, Multiple Sclerosis (83). 
 The late 19th Century and first half of the 20th Century heralded 
major advances in the diagnosis and treatment of infectious diseases.  
For example, during the first half of the 1914 – 1918 War tetanus was a 
major cause of mortality in wounded troops; however, the swift 
implementation of mass tetanus vaccination of troops and adequate 
wound toilet resulted in the virtual elimination of tetanus from 1916 
onwards (84).  Paul Ehrlich was the first to develop non-poisonous, 
effective antibacterial agents (eg. Salvarsan) and during the late 1920s 
Sir Alexander Fleming was in the process of discovering penicillin.  The 
capacity to identify the aetiological agent of disease enabled the 
process of learning how to diagnose and treat that disease.  It is, 
therefore, not surprising that scientific opinion was biased towards 
treating multiple sclerosis as an infectious disease in the hope that a 
cure might be found.  An address (85) given by Douglas McAlpine on 
disseminated sclerosis in 1927 encapsulated the prevailing views of the 
time as exemplified by the following excerpts from the published paper.   
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“Further clinical evidence is afforded by the characteristic 
relapses and remissions which occur during the course of the 
disease in the majority of cases.  Any theory which attributes the 
condition to developmental errors falls to the ground in the 
presence of the curious variations in the clinical picture.  In this 
respect disseminated sclerosis resembles meningo-vascular 
syphilis, pulmonary tuberculosis, and other chronic infections.  
The variations in the intensity of the infective process can be 
best explained by supposing that a virus, or its toxin, periodically 
invades the central nervous system, so producing a train of 
symptoms which will depend on the particular part of the neuro-
axis attacked.” 
Excerpt from an address given by Douglas McAlpine, M.D., M.R.C.P., 
to the Oxford Division of the British Medical Association, published in 
the Lancet, February 12, 1927 (85). 
 While the prevailing view that the aetiology of multiple sclerosis 
was infectious the choice of treatments adopted reflected experience 
with genuine infectious diseases and, consequently, yielded little 
benefit for the patient.  In 1950, a series of articles published in the 
Journal of the American Medical Association (86, 87) by George A. 
Schumacher reviewed the state of past treatment options as follows. 
“Numerous modes of therapy have become obsolete despite 
original contentions of their value.  Among these use of 
antiseptics, especially arsenic, fever therapy, various vaccines, 
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and serums, autohemotherapy, belladonna, endocrine 
substances and penicillin.  It may be safely stated that these 
measures have proved largely ineffective.” 
Excerpt from a paper (86) by G. A, Schumacher, JAMA 1950; 143: 
1146-1154. 
 During the 1950s there was a move away from infection as a 
cause of multiple sclerosis towards “allergic theory” and the 
consideration of multifactorial causation (88).  Henry Miller and Kurt 
Schapira in an article (89) published in the British Medical Journal 
described allergic theory thus. 
“As we see it, what may be broadly termed the allergic 
hypothesis may be briefly developed in the following terms.  The 
initial lesion in multiple sclerosis appears to be focal, 
disseminated microscopic perivenous exudation and oedema.  
This is accompanied or followed by an inflammatory reaction of 
variable intensity at the same site, which is in turn succeeded 
there by the well-defined demyelination and glial proliferation 
typical of the established disease...there is good reason to 
believe that the initial perivenous lesion which is the first visible 
pathological sign of the disease represents in itself the larval 
manifestation of neural hypersensitivity” 
Excerpt from a paper (89) by Henry Miller, M.D, F.R.C.P. and Kurt 
Schapira, M.B. published in the British Medical Journal, March 28, 
1959.  
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 The recently established experimental allergic encephalomyelitis 
model in animals had shown that injection of the sterile extracts of 
animal nervous tissue could result in the development of analogous 
lesions (90); therefore, the direct involvement of infectious agents was 
equivocal.  Around this time steroids had been shown to have a positive 
benefit in the treatment of rheumatoid arthritis (91) and the first trials of 
steroid treatment of multiple sclerosis were undertaken; however, the 
results were disappointing (92).  Despite the initial setbacks, steroid 
treatment has now become an established treatment for relapse; 
however, although recovery can be hastened by their use, they have 
little impact on the final degree of recovery or the overall progression of 
disease, and optimum treatment regimens still remain to be determined 
(93, 94). 
1.3.2 Disease modifying treatments for multiple sclerosis 
 Disease modifying treatments have been shown to influence the 
course of relapsing and remitting multiple sclerosis; however, they have 
little or no effect on the progressive form of the disease (95).  An 
extensive review of disease modifying treatments, established or under 
development, is beyond the scope of this thesis and only some specific 
comments will be made relating to established first-line treatments, 
newly available oral drugs, and monoclonal antibody based 
therapeutics. 
The first widely used and effective and relatively non-toxic 
disease modifying treatment to become available was interferon β.  
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Initially, the interferons had been discovered as agents that inhibited 
influenza virus multiplication (96) and had been of interest because of 
their antiviral activity; however, during the 1980s their role in the 
potential treatment of multiple sclerosis was assessed.  Interferon γ 
treatment was associated with an increased rate of exacerbations; 
however, trials with interferons α and β yielded promising results (97).  
In these early studies, purified interferon preparations were used which 
were difficult and costly to produce.  Genetic engineering resolved this 
difficulty; for instance, interferon β-1b has been produced which retains 
the activity of the natural form but has greater stability due to the 
replacement of a cysteine residue by a serine residue at position 17, 
and it is not glycosylated.  Alternative forms of interferon β (IM IFN-β1a 
& SC IFN-β1a) comprising the native amino acid sequence are also 
available giving a choice of route of administration (98).  The costs of 
standard treatment packages of interferon β-1b (250 μg SC), IM IFN-
β1a (30 μg) and SC IFN-β1a (44 μg) are approximately €800 monthly 
(99).  Development of flu-like symptoms and local skin reactions are 
common adverse events/side effects together with depression, and the 
production of neutralizing antibodies which may be problematic; 
however, numerous clinical trials have established efficacy and a 
reasonable long-term safety profile (100, 101). 
 A survey (102) of current European treatment practices for the 
initial stages of relapsing and remitting multiple sclerosis showed 37% 
of neurologists to use interferon β preparations, 25% to use dimethyl 
fumarate, 22% to use teriflunomide, and 9% to use glatiramer acetate, 
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as first line therapy.  Dimethyl fumarate is a fumaric acid derivative 
(103) that is metabolized in the gastrointestinal tract to monomethyl 
fumarate – the active component.  Initially, it was used for the treatment 
of psoriasis; however, in vivo studies (104) in the experimental allergic 
encephalomyelitis (EAE) model showed potential for the treatment of 
multiple sclerosis.  Subsequent clinical trials have shown administration 
of the drug to significantly reduce relapse rates through yet 
incompletely elucidated mechanisms of action that include induction of 
a shift to aTH2 immune response (105).  Obviously, an attractive 
therapeutic agent because it can be taken orally; however, a recent 
post-approval study has raised concerns of a comparative lack of 
efficacy and discontinuation due to lymphopenia and gastrointestinal 
side effects (106).  Finally, there have been reports of progressive 
multifocal leukoencephalopathy in patients treated with this drug (107). 
Teriflunomide, like dimethyl fumarate can be taken orally.  It is an anti-
inflammatory agent, which was initially used to treat another 
autoimmune disease (rheumatoid arthritis) that has subsequently been 
shown in EAE animal models to have potential efficacy for the 
treatment of multiple sclerosis (108).  It is an active metabolite of 
leflunomide that inhibits dihydroorotate dehydrogenase activity, which is 
essential for the pyrimidine synthesis required by rapidly proliferating, 
activated lymphocytes (109).  Teriflunomide has also been shown to 
display pyrimidine synthesis independent effects on the immune system 
including the disruption of T cell interactions with antigen presenting 
cells and modulation of cytokine activity towards the induction of a TH2 
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response (110).  Two major placebo-controlled clinical trials have been 
conducted to determine the efficacy of teriflunomide in patients with 
relapsing multiple sclerosis (111) and these showed significant dose-
dependent reductions in annualized relapse rates (p<0.001) and 
disability scores (p<0.1).  The drug is teratogenic and side effects 
include hair loss and raised liver transaminases (112). 
 We are now in an era where targeted biotherapeutics can be 
designed and produced for specific immunological pathways.  The 
production of monoclonal antibodies using hybridoma technology, first 
described by Köhler and Milstein in 1975 (113), enabled limitless 
quantities of reproducible and specific immunoglobulins to be produced 
from immortalized cell lines.  Unfortunately, the therapeutic use of such 
molecules was greatly limited because the human immune system 
recognized them as “foreign”.  Advances in antibody engineering have 
made possible the production of therapeutic monoclonal antibodies by 
“humanizing” adaptations combined with the application of other 
bioengineering structural modifications to improve pharmacokinetics 
(114).  Consequently, a range of therapeutic monoclonals have been 
produced for a variety of applications including the treatment of multiple 
sclerosis (Table 1) raising the possibility of major advances in the 
treatment options available for this disease (115).   
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Table 1.  Therapeutic monoclonal antibodies and their targets for 
relapsing and remitting multiple sclerosis treatment. 
 
Therapeutic 
monoclonal 
Principal mechanism 
of action 
Concerns and 
limitations  
Alemtuzumab – 
humanized anti-
CD52 (116) 
Immunomodulation 
through the depletion 
of B and T cells and 
subsequent changes 
to subsets upon 
repopulation. 
Risk of herpes virus 
infections following 
administration. 
Increased risk of 
development of 
autoimmune conditions. 
Daclizumab – 
humanized anti-
CD25 (117)  
Immunomodulation 
through a number of 
effects following 
binding to the 
interleukin-2 receptor 
including the 
expansion of 
regulatory natural killer 
cells. 
Increased risk of 
infections, elevated liver 
enzymes and skin 
reactions.  Possible 
induction of 
autoimmune conditions. 
Natalizumab – 
humanized anti-
α4β1 integrin 
antibody (118) 
Disrupts leukocyte 
migration to sites of 
inflammation by 
blocking the VLA4 
integrin receptor 
present in leukocytes 
thereby preventing 
binding to activated 
adhesion (VCAM-1) 
receptors  expressed 
by vascular 
endothelium cells. 
Major safety concern is 
the risk of progressive 
multifocal 
leukoencephalopathy.  
Ocrelizumab – 
humanized anti-
CD20 (119) 
 
 
Rituximab used as a 
treatment for 
rheumatoid arthritis 
is another anti-
CD20 antibody with 
application against 
multiple sclerosis 
(120) 
Depletes B cells 
except early precursor 
and plasma forms 
(which do not express 
CD20) through 
antibody-dependent 
cellular cytotoxicity 
and complement-
mediated lysis. 
Immunosuppressive 
and decreased 
immunogenicity 
(vaccination 
contraindicated).  
Increased risk of 
infections, particularly 
respiratory tract.  
Herpes viruses 
reactivations.  Infusion 
related reactions.  
Concern over potential 
increased risk of 
malignancy. 
  
  21 
1.3.3 Helminth therapy – an alternative option for treating multiple 
sclerosis  
 Helminth therapy was first reported to be effective in the 
treatment of human inflammatory conditions in 2005 (121).  
Subsequent clinical trials yielded variable results in relation to efficacy 
although tolerability was generally good (122).  Several EAE mouse 
model studies (123, 124) have shown that helminths, or their products, 
have potential as treatments for multiple sclerosis.  Epidemiological and 
observational data (see section 1.2.4) also support the potential 
application of helminth therapy in the treatment of multiple sclerosis.  
There are limited clinical trial data (<100 patients) that generally support 
further clinical investigations of helminth therapy for multiple sclerosis 
and these have been reviewed by Tanasescu and Constantinescu 
(125). 
 The University of Nottingham and Nottingham University 
Hospitals have undertaken the largest clinical trial (NCTC1470521) of 
helminth therapy for multiple sclerosis, to date.  In this study (WIRMS), 
which is randomized, placebo-controlled, and double-blind in design, 36 
patients presenting with a range of forms of multiple sclerosis 
(predominantly relapsing and remitting) have been infected with 
Necator americanus (human hookworm) and a similar group have 
received placebo.  The trial period was for one year during which time 
patients were closely monitored and at nine months they received 
mebendazole to eradicate helminth infection.   The primary measure of 
efficacy was based on the cumulative number of new or enlarging 
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Gadolinium-enhanced lesions after nine months.  Samples were taken 
at defined periods of the trial for the measurement of biochemical, 
immunological, and parasitological parameters. 
  There are significant concerns with the application of helminth 
therapy relating to safety, efficacy, and other factors (126).  Parasites 
such as N. americanus are human pathogens themselves.  The life 
cycle of N. americanus is shown in figure 1 and immediate safety 
concerns relate to the risk of pulmonary damage during larval transit, 
anaemia following gastrointestinal blood loss and adverse effects on 
airways responsiveness (127).  Efficacy will be dependent on various 
factors (128); for example, commencement of treatment in the early 
stages of multiple sclerosis appears to yield the best results.  
Additionally, establishment of the longer-term (> 1 year) benefits or 
limitations of treatment is needed.  Optimisation of dosing schedules 
and the helminth load to be administered is required.  The 
reproducibility and safety of manufacturing processes remains to be 
established.  Finally, the use of helminth products instead of live 
helminth treatment requires evaluation at many levels ranging from 
identifying the immunological mechanisms involved (124, 129, 130) to 
final optimal clinical usage. 
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Figure 1.  Life cycle of Necator americanus 
 
 
 
Legend. 
Eggs (1) are passed in the stool and larvae hatch under favourable 
conditions.  The rhabdatiform larval form (2) matures in the soil or 
faeces.  The infective filarial form (3), on contact with the human host 
(4) penetrates the skin and is transported via the blood to the heart and 
then to the lungs.  Following transpulmonary migration larvae ascend 
the bronchial tree to the pharynx and are swallowed.  The larvae attach 
to the wall of the small intestine and mature into adults (5).  This stage 
is associated with intestinal blood loss. 
Life cycle image courtesy of CDC Division of Parasitic Diseases and 
Malaria and is supplied free of copyright as an educational resource 
(see www.cdc.gov/parasites/.)   
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1.4 Human herpesviruses and multiple sclerosis 
1.4.1 The Human herpesviruses 
 Over 100 species of herpes viruses have been identified and 
they have been isolated from a wide variety of hosts including humans, 
non-human primates, other mammals, birds, amphibians and reptiles 
(131).  Common features of these viruses include a linear, double-
stranded DNA genome, contained within an icosahedral capsid 
structure, together with the possession of a tegument and lipid 
envelope, and the capacity to establish host latency.  In recent years 
(132), the taxonomy of the herpes viruses has been updated with the 
establishment of the order Herpesvirales comprising three families – 
Herpesviridae (avian, mammalian, and reptilian viruses), 
Alloherpesviridae (amphibian and piscine viruses) and 
Malacoherpesviridae (molluscan viruses).  Within the family 
Herpesviridae there are three subfamilies – Alphaherpesvirinae, 
Betaherpesvirinae, and Gammaherpesvirinae and human herpes 
viruses are represented in each of these subfamilies (133).  There are 
eight human herpesviruses (Table 2) and in this study the serological 
profiles from a representative of each subfamily (HHV-3, HHV-4 and 
HHV-5) have been determined.  The financial and time constraints of 
the project influenced this approach together with the fact that previous 
studies have shown the selected viruses to be of significant interest.  
Pros and cons for investigating the serological profiles of the other 
human herpesviruses (HHV-1, HHV-2, HHV-6, HHV-7 and HHV-8) are 
discussed in section 5.4 (pt 5) which addresses potential future work.  
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Table 2.  The human herpesviruses 
 
Taxon name/ 
Subfamily 
 
Genus Common name/ 
Clinical condition(s) 
Human herpesvirus 1 
Alphaherpesvirinae 
 
Simplexivirus Herpes simplex virus type 1 
(HSV-1). 
Primary infection: Herpetic 
skin infections (eg. 
stomatitis), conjunctivitis, 
encephalitis. 
Reactivation: cold sores. 
HSV-2 may cause these also. 
Human herpesvirus 2 
Alphaherpesvirinae 
 
Simplexivirus Herpes simplex virus type 2 
(HSV-2). 
Primary and recurrent genital 
herpes.  Neonatal herpes.  
HSV meningitis.  HSV-1 may 
cause these also. 
Human herpesvirus 3 
Alphaherpesvirinae 
 
Varicellovirus Varicella-zoster virus (VZV). 
Primary infection: Chickenpox 
(varicella). 
Reactivation: Shingles 
(zoster). 
Human herpesvirus 4 
Gammaherpesvirinae 
 
Lymphocryptovirus Epstein-Barr virus (EBV). 
Infectious mononucleosis 
(glandular fever). 
Lymphoproliferative diseases 
(eg. post-transplant)   
Lymphomas (eg. Hodgkin). 
Human herpesvirus 5 
Betaherpesvirinae 
 
Cytomegalovirus Human cytomegalovirus 
(CMV). Congenital infection. 
Mononucleosis syndrome. 
Post-transplant infections 
(primary or recurrent) 
eg. pneumonitis. 
Human herpesvirus 6 
Betaherpesvirinae 
 
Roseolovirus Human herpes virus 6A 
(HHV-6A) and 6B (HHV-6B). 
Primary infection: fever 
and/or roseola /sixth disease.  
In some cases, encephalitis. 
Reactivation: post-transplant  
Illness including encephalitis. 
Human herpesvirus 7 
Betaherpesvirinae 
 
Roseolovirus Human herpes virus 7. 
Primary infection: fever 
and/or roseola.  Neurological 
sequlae including seizures. 
Human herpesvirus 8 
Gammaherpesvirinae 
Rhadinovirus Human herpes virus 8. 
Kaposi sarcoma. 
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1.4.2 Human herpesvirus 3 (Varicella-Zoster virus) 
 
 Commonly known as Varicella-Zoster virus (VZV), human 
herpesvirus 3 is an alpha herpesvirus.  The virus genome of 
approximately 125,000 base pairs (125 kbps) encodes at least 70 
genes and comprises a unique long region (100 kbp) and unique short 
region (5.4 kbp) flanked by internal and terminating repeat regions 
(134).  The virus shows very low genetic diversity on comparison with 
other herpes viruses (135).  Based on internationally agreed criteria 
and nomenclature (136) five VZV clades (1, 2, 3, 4, and 5) have been 
designated together with several provisional clades (VI, VII, VIII and IX); 
however, in clinical, serological and virological properties they can all 
be considered the same.  Structurally, the VZV virion is of variable size 
(120nm – 300nm) due to the varying thickness of the tegument and the 
virus envelope comprises host cell membrane with virus derived 
glycoprotein spikes projecting on its surface, (137).  Several surface 
glycoproteins have been described that display a range of functions key 
to virus pathogenicity; for instance, glycoproteins gE and gI interact to 
present the virus Fc receptor and glycoproteins B and C have a role in 
cell attachment and virus absorption (138). 
 Primary infection with VZV manifests as chickenpox, and by age 
10 years most English and Welsh children have been infected (139).  
Chickenpox is typically a self-limiting infection of childhood in 
immunocompetent children; however, in adults, pregnant women, and 
the immunodeficient, complications of chickenpox (eg. varicella 
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pneumonia, encephalitis) can result in significant morbidity and even 
mortality (140).  Transmission of VZV is principally by the respiratory 
route through aerosols (141) and the vesicles produced during the 
infection initially contain high titres of cell-free virus and represent an 
infection risk.  Initially, VZV infects the respiratory epithelia of the upper 
respiratory tract; in particular, tonsillar lymphoid tissue where T cells are 
preferentially infected (142) which then enter the circulation generating 
a short-lived viraemia.  Dissemination of the virus leads to infection of 
cutaneous epithelial cells, where local immune responses are, initially, 
insufficient to prevent extensive virus multiplication leading to vesicle 
formation.  At some stage, neurons of the sensory ganglia are infected 
and virus latency established.  Zoster, or shingles, results when latent 
virus reactivates; hence, the characteristic dermatomal distribution of 
the rash.  The precise factors responsible for virus reactivation remain 
to be fully described; however, zoster is associated with a general 
decline in immune function and is characteristically seen in the later 
years of life in immunocompetent individuals (143).  Alternatively, zoster 
can be a complication of immunodeficiency or processes leading to 
immune suppression in individuals of any age (144). 
 Several studies have reported an association of a history of VZV 
infection with multiple sclerosis.  Ross and colleagues (145) have 
observed that the geographical and temporal prevalences of multiple 
sclerosis and varicella appear to be linked and in a control study, 
Rodríguez-Violante and co-workers (146) have reported an increased 
risk of association of a history of varicella and having multiple sclerosis.  
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Other studies (147) have failed to yield sufficient evidence in support of 
a significant relationship between VZV infection and multiple sclerosis.  
While an association between varicella or zoster and the development 
of multiple sclerosis is a matter for debate there is ample evidence that 
certain treatments for multiple sclerosis predispose to VZV infection and 
reactivation.  For instance, treatment with fingolimod has resulted in 
fatal disseminated primary VZV infection (148) and treatment with 
alemtuzumab has been shown to give a higher rate of herpes zoster 
compared to interferon beta-1a (149). 
1.4.3 Human herpesvirus 4 (Epstein-Barr virus) 
 First described in 1964 following electron microscopy of 
cultivated human lymphoblasts from Burkitt’s malignant lymphoma 
(150), Epstein-Barr virus (EBV) is a gamma herpesvirus (151), 
designated Human herpesvirus 4.  The EBV virus genome of double-
stranded DNA is linear in the virus particle, but is circularized as an 
episome within the nuclear compartment of infected cells.  The 
complete nucleotide sequence of EBV is approximately 172,000 base 
pairs and two virus subtypes have been described, EBV1 and EBV2 
that show close co-linear sequence alignments with each other (152, 
153) apart from a number of known diverged alleles (154).  In terms of 
organization, there are terminal, tandem-repeat regions (joined during 
circularization) separated by unique short and unique long regions 
interspersed with four internal repeat regions (155). 
  29 
 The expression of virus proteins varies between the latent and 
lytic phases of virus growth (156).  Primary EBV infection commences 
with infection of oropharyngeal epithelial cells via saliva containing shed 
virus through complex pathways (157).  EBV infection of B cells is much 
more efficient and virus binds to specific receptors on the cell surface; 
for example, the virus glycoprotein gp 350 (158) binds to a B-
lymphocyte membrane receptor (CD21) which also binds complement 
C3d (159).  Following entry into epithelial or B cells by virus 
endocytosis, a number of replicative strategies and interactions with the 
host immune system can then follow resulting in lytic infection or the 
establishment of latency (160).  In EBV-transformed lymphoblastoid cell 
lines, a number of latency states (types 0, I, II, or III) have been 
described and these reflect the differing levels of expression of virus 
latency-associated proteins by infected B cells (161).  These proteins 
include the Epstein-Barr nuclear antigens (EBNA-1, EBNA-2, EBNA-3A, 
EBNA- 3B, EBNA-3C, and EBNA-LP) and latent membrane proteins 
(LMP1, LMP2A, and LMP2B).  EBNA-1 is a DNA binding nuclear 
phosphoprotein and it is expressed in all latency types, and has 
multiple and important roles in EBV infection.  Key functions of EBNA-1 
include roles in the replication and mitotic separation of EBV episomes, 
the activation of other latency associated genes, and in lytic infection it 
acts as a gene expression promoter (162).  Another important aspect of 
EBNA-1 expression is that EBNA-1 specific T cells have been shown to 
recognize myelin basic protein (163) raising the possibility of molecular 
mimicry (164).  EBNA-1 is expressed in latency states I, II and III 
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whereas EBNA-2 is expressed in latency states II and III and the 
EBNA-3 proteins are expressed in latency state III.  Young and 
Rickinson (165) have reviewed the roles and functions of these and 
other relevant proteins, which will not be described here.  Ultimately, 
irrespective of the latency state adopted, EBV maintains persistence 
throughout life in memory B cells (sIg+, IgDneg) only (166).  During initial 
infection (or intermittent shedding) EBV can be shed by both B cells 
and epithelial cells (167); however, episodes of reactivation follow the 
induction of the lytic phase in B cells and are accompanied by the 
expression of approximately 80 lytic phase specific genes.  This highly 
complex process, involving early and late lytic proteins of varying 
immunodominance and in which the CD8 T cell response plays a key 
role, has been comprehensively reviewed by Hislop and colleagues 
(168).   
 Epstein-Barr virus infection usually occurs during childhood and 
in most cases, is asymptomatic (169).  Marked differences in the age of 
acquisition, related to race and socioeconomic factors, have been 
reported (170) and there is an increasing tendency towards higher ages 
of acquisition in England and Wales (171).  Infection during 
adolescence and adulthood is more likely to present as infectious 
mononucleosis (glandular fever), which typically presents as pharyngitis 
and cervical lymphadenopathy, frequently with hepatitis, and with 
reported severe sore throat, fatigue, fever and headache (172).  In a 
small number of cases primary infection does not resolve and chronic 
active disease evolves which carries a high risk of significant morbidity 
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and mortality (173).  EBV is an oncogenic virus and is primarily 
associated with B-cell lymphomas and nasopharyngeal carcinoma 
(174), which are uncontrolled proliferations of B-lymphocytes and 
tonsillar epithelial cells, respectively, which are the cells it initially 
infects.  Critical to control of EBV reactivation is the suppression of EBV 
reactivation by the host immune system (175).  Compromise of host 
immune function either through genetic defect, disease (eg. AIDS, 
malaria), or immunosuppressive treatment, such as that used for 
transplantation, carries an increased risk of neoplasm generation.  For 
instance, in X-linked lymphoproliferative disease (XLP) triggered by 
EBV infection, 70% mortality has been reported by age 10 years, which 
is due to mutations of the SH2D1A gene resulting in fulminant 
infectious mononucleosis, dysgammaglobulinaemia and lymphoma 
(176).  While XLP is a rare primary immunodeficiency, post transplant 
lymphoproliferative disorder (PTLD) is a significant risk of the induced 
immunosuppression required to prevent rejection of transplanted 
organs or tissues (177).  The degree of risk of PTLD has been shown to 
be highly associated with the extent and severity of immunosuppression 
induced (178).  EBV is also associated with tumour formation in 
immunocompetent individuals through, as yet, incompletely explained 
mechanisms.  In nasopharyngeal carcinoma there is a complete 
association with EBV and in Hodgkin’s lymphoma there is an 
approximately 40% association (179).  
 The association of EBV infection with several autoimmune 
diseases (eg. systemic lupus erythematosus, rheumatoid arthritis, 
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primary Sjögren’s syndrome) has been reported (180).  In the case of 
multiple sclerosis in adults, virtually 100% linkage has been reported 
with the detection of serological markers, particularly EBNA-1 IgG, of 
past EBV infection (181).  It has also been shown (182) that the risk of 
multiple sclerosis developing in EBV seronegative individuals is very 
low.  A problem with assessing the relevance of serological markers of 
past infection with EBV in adults is that the sero-prevalence in control 
subjects is also usually very high, approximately 95% by age 30 years 
(183).  In children, the control population EBV seroprevalence is lower 
and a comparable risk for the development of multiple sclerosis to 
adults has been found (184).  A history of infectious mononucleosis is 
positively associated (relative risk 2.17; 95% CI: 1.97-2.39) with the 
development of multiple sclerosis (185).  High levels of EBNA-1 IgG 
have been shown to be associated with an increased risk of 
development of multiple sclerosis (186) and several studies (187-189) 
have shown that levels of EBNA-1 IgG are elevated in individuals with 
multiple sclerosis compared to controls.  There have been reports that 
serum levels of EBNA-1 IgG correlate with multiple sclerosis disease 
activity.  In a study (190) by Farrell and colleagues, 50 clinically isolated 
syndrome (CIS), 25 relapsing-remitting multiple sclerosis (RRMS), and 
25 primary progressive multiple sclerosis (PPMS) patients were 
monitored for EBNA-1 IgG plus other EBV infection markers over a 
period of five years.  Multiple sclerosis disease activity was assessed 
by the serial monitoring of gadolinium-enhanced (Gd+) lesions.  EBNA-
1 IgG levels were significantly elevated (p<0.001) in the RRMS group 
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compared to the CIS and PPMS groups and there was a degree of 
positive correlation (r=0.3) between EBNA-1 IgG and EBNA-1 IgG 
levels.  In another study (191), 87 multiple sclerosis patients were 
followed for two years and multiple sclerosis disease activity was 
monitored by Gd+ scans.  Higher EBNA-1 IgG levels were associated 
with increased disease activity over the total study period (p<0.05).  
Other studies have reported no association between EBNA-1 IgG levels 
and multiple sclerosis disease activity at least in the early stages of 
disease (192, 193).     
 EBV reactivation can have serious complications in the 
immunocompromised host, as described earlier.  In multiple sclerosis, 
several studies have reported EBV reactivation to be associated with 
disease activity.  For instance, Wandinger and colleagues (194) 
followed 19 multiple sclerosis patients monthly for one year and 
detected virus markers of reactivation in 72.7% of patients with 
exacerbations and in none with clinically stable disease.  Both Buljevac 
and colleagues (195) and Latham and colleagues (196) have provided 
limited evidence that EBV reactivation is associated with episodes of 
relapse.  A number of other studies (193, 197-199) have presented 
evidence that there is no association of EBV reactivation with multiple 
sclerosis disease activity.  Clearly, the impact of EBV reactivation on 
multiple sclerosis disease activity requires further investigation. 
1.4.4 Human herpesvirus 5 (Human Cytomegalovirus) 
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 Human cytomegalovirus (HCMV) is a betaherpesvirus and this 
group of herpesviruses typically shows tropism for the salivary glands, 
grows slowly in cell culture, and exhibits strict species specificity (200).  
Structurally, HCMV virions are 120-200 nm in diameter with an 
enveloped, icosahedral capsid containing the linear double-stranded 
DNA genome.  The genome is the largest of the human herpesviruses 
comprising approximately 235,000 base pairs and housing a 
complement of 165 genes (201).  At least 80% nucleic acid homology 
exists among HCMV strains (202); however, HCMV isolates display 
considerable antigenic and genotypic diversity (203).  HCMV infects a 
wide variety of cell types and displays both endothelial and leukocyte 
cell tropisms (204).  Virus latency is established in cells of myeloid 
lineage and virus reactivation has been shown to follow allogeneic T-
cell stimulation of latently infected monocytes (205).  In endothelial and 
epithelial cells low-level virus shedding has been shown to last for years 
and mechanisms of latency, reactivation or chronic infection remain to 
be defined or excluded (206). 
 In immunocompetent children and adults, HCMV infection 
typically is not accompanied by clinically obvious disease.  HCMV is 
found worldwide and seroprevalence increases with age (207).  Higher 
seroprevalences have been reported in developing countries/regions of 
lower socioeconomic status (208).  In England and Wales, HCMV 
seroprevalence has been reported to range from approximately 15% in 
those aged 1-4 years, 30-50% in those aged 30-40 years, and 
approximately 80% in those aged 65 years, or older (209).  HCMV is a 
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major cause of congenital infection and 10-15% cases are 
symptomatic, commonly presenting with clinical signs including 
hepatosplenomgaly, and neurological development abnormalities (210).  
Sensorineural hearing loss is a major complication of HCMV congenital 
infection occurring in 30-40% of symptomatic cases and 5-10% of 
asymptomatic cases (211).  HCMV mediated disease either following 
primary infection, or reactivation, or reinfection is a major cause of 
morbidity and mortality in immunocompromised individuals.  Before the 
effective control of HIV infection by highly active anti-retroviral therapy 
(HAART), HCMV retinitis, gastroenteritis or neurological disease were 
frequent and severe complications in individuals with low (<100/μl) CD4 
cell counts (212).  These days, severe HCMV infection is most 
frequently encountered in organ or stem cell transplant recipients at the 
height of their immunosuppression usually >90 days post transplant 
(213).   
 Unlike EBV infection, based on seroprevalence data there 
appears to be no linkage between the development of multiple sclerosis 
and HCMV infection (214, 215).  In fact, it has been suggested that 
HCMV seropositivity is negatively associated with the development of 
multiple sclerosis in children (216) and adults (217).  Recently, it has 
been reported that CMV infection is associated with neurodegeneration 
(218) and exacerbates autoimmune mediated neuroinflammation (219).  
It has been suggested (220, 221) that HCMV infection drives the 
expansion of CD4+CD28null cells, which are highly pro-inflammatory and 
less susceptible to suppression by T regulatory cells resulting in the 
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potential for autoreactive attack and destruction of myelin. Milovanovic 
and colleagues (222), who investigated murine cytomegalovirus 
infection, have presented additional evidence supporting the 
contribution of CMV infection to the exacerbation of autoreactive 
processes.  Several studies have reported an immunomodulatory effect 
related to CMV infection and the only common denominator is that this 
is a controversial topic and that further studies are required to help 
elucidate the impact of HCMV infection on multiple sclerosis (223).  
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2.0 RATIONALE, AIMS, OBJECTIVES, AND STUDY 
PLAN 
2.1 Study rationale 
 Worldwide it is estimated that there are 2.3 million cases of 
multiple sclerosis (31) and it is one of the leading causes of disability in 
adults.  The disease arises in genetically predisposed individuals as a 
consequence of environmental exposures (see section 1.2.1); however, 
although associations have been identified (eg. Epstein-Barr virus 
infection, vitamin D levels, socio-economic status, smoking) its 
causation remains to be identified.  New disease-modifying treatments 
are increasingly available (see section 1.3.2) and although they are 
effective in reducing the number and rate of relapses they are not 
curative.  Unfortunately, the treatments available are expensive and 
have potentially serious side effects (224).  Helminth therapy represents 
an alternative approach in that it is inexpensive and potentially 
preventative (see section 1.3.3).  As with any new therapeutic approach 
efficacy has to be established and potential side effects identified. 
 In 2012 the WIRMS study commenced at Nottingham University 
and hospitals and this was a randomized, double-blinded, placebo 
controlled study of hookworm treatment of multiple sclerosis.  A total of 
72 patients were enrolled, 36 were infected with 25 larvae of Necator 
americanus and 36 were given placebo.  At the time of commencement, 
this was the largest study so far performed to assess the efficacy and 
safety of helminth therapy.  Subsequently, the possibility that helminth 
therapy might induce Epstein-Barr virus (EBV) reactivation has been 
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raised.  Reese and colleagues have reported (225) that helminth 
challenge/infection of mice previously infected with the murine gamma 
herpesvirus (MHV68) blocked the antiviral activity of interferon-γ and 
promoted virus replication and that in cell culture experiments 
reactivation of herpesvirus was induced.  In a separate study using 
mice (130), Osborne and colleagues have shown helminth infection to 
have specific immunomodulatory effects on antiviral immunity.  No data 
is available on the impact of helminth therapy on EBV reactivations in 
multiple sclerosis patients and because of the recently published animal 
data further investigation is warranted. 
 Other herpesviruses (eg. CMV and VZV) also widely infect 
humans and have the capacity to establish latency (see section 1.4).  
Certain disease modifying treatments (eg. fingolimod) have been 
associated with an increased risk of VZV reactivation (226).  No data is 
available on how helminth treatment might impact on the humoral 
immunity of multiple sclerosis patients to α-herpesviruses and β-
herpesviruses.   
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2.2 Study aim and objectives 
2.2.1 Aim    
To measure over a period of one-year antibody levels of selected 
herpes viruses and identify cases of reactivation in a group of multiple 
sclerosis patients therapeutically infected with Necator americanus and 
a group of placebo controlled patients recruited to the Nottingham 
WIRMS study. 
2.2.2 Objectives 
1. Characterize herpes virus antibody responses over time in N. 
americanus treated and untreated patients. 
2. Determine if N. americanus treatment results in reactivations of 
α-, β, or γ-  herpesviruses.  
3. Investigate potential linkages between multiple sclerosis disease 
activity and herpesvirus antibody markers and levels. 
4. Show if antibody levels are stable over time. 
5. Calculate the reproducibility of the antibody detection assays 
used. 
 2.3 Study plan 
 Sera collected at defined time intervals during the recently 
completed Nottingham WIRMS clinical trial (NCT 01470521) were used 
for this study for which ethical approval had been obtained.  The study 
comprised two phases; firstly, laboratory testing undertaken by PACM 
who had no prior access to treatment allocations (unbiased phase) or 
other patient clinical data.  In the second phase, on completion of 
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laboratory testing and the documentation of results, treatment 
allocations and basic patient demographic data were made available to 
PACM, so that relevant analyses could be undertaken.  The patients 
had monthly examinations and MRI scans between the third and ninth 
months of the trial and stool ova counts were measured over the period 
of the trial.  In both cases, clinical interpretation (eg. MRI) and ova 
counting was conducted by individuals with no knowledge of treatment 
allocations.  
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3.0 MATERIALS AND METHODS 
3.1 Equipment and materials used 
3.1.1 Control sera 
SERION ELISA classic (Institut Virion\Serion GmbH, Würzburg, 
Germany) control sera were obtained from Launch Diagnostics (New 
Ash Green, Longfield, Kent, UK) and upon receipt were stored at 6oC 
+/– 2oC.  Details of control sera are shown in Table 3. 
3.1.2 Deionized water 
  Deionized water (LAB 3 Ltd, code WA11200-275) was obtained 
from VWR International Ltd, Magna Park, Lutterworth, Leicestershire, 
UK. 
3.1.3 Enzyme immunoassay kits (EIAs) 
 SERION ELISA classic (Institut Virion\Serion GmbH, Würzburg, 
Germany) kits were obtained from Launch Diagnostics (New Ash 
Green, Longfield, Kent) and upon receipt were stored at 6oC +/– 2oC.  
Details of kits are shown in Table 3. 
3.1.4 Microplate reader 
 A BioRad Benchmark Plus microplate spectrophotometer was 
used to read optical densities. 
3.1.5 Microplate washer 
 A Thermoscientific WELLWASH microplate washer (Cat no. 
5165000) was used to wash microplates. 
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3.1.6 Rheumatoid factor 
SERION ELISA classic (Institut Virion\Serion GmbH, Würzburg, 
Germany) rheumatoid factor absorbent (Z200, lot SGG.CV, expiry 
2018-07) was obtained from Launch Diagnostics (New Ash Green, 
Longfield, Kent) and upon receipt was stored at 6oC +/– 2oC. 
Table 3.  Details of SERION ELISA classic kits and control sera 
used 
 
ELISA kit/Control serum Kit code Batch ID Expiry 
Cytomegalovirus IgG 
ELISA 
ESR109G SHG.EN 2018-08 
Cytomegalovirus IgG 
control serum 
BC109G SHG.BB 2018-08 
Epstein-Barr virus EA IgG 
ELISA 
ESR1363G SHF.DP 2017-08 
Epstein-Barr virus EA IgG 
control serum 
BC1363G SGG.GH 2018-07 
Epstein-Barr virus EBNA-1 IgG 
ELISA 
ESR1362G SLG.CA 2018-10 
Epstein-Barr virus EBNA-1 IgG 
control serum 
BC1362G SGG.GI 2018-07 
Epstein-Barr virus EBV VCA IgG 
ELISA 
ESR1361G SHG.AU 2018-07 
Epstein-Barr virus EBV VCA IgG 
control serum 
BC1361G SGG.GK 2018-07 
Epstein-Barr virus EBV VCA IgM 
ELISA 
ESR1361M SFG.GW 2018-06 
Epstein-Barr virus EBV VCA IgM 
control serum 
BC1361M SHG.CP 2018-08 
Varicella-zoster virus IgG 
ELISA 
ESR104G SHG.AN 2018-06 
Varicella-zoster virus IgG 
control serum 
BC104G SKF.BA 2017-10 
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3.2 Study population 
 The serum samples tested were collected as part of the WIRMS 
(Worms for Immune Regulation in MS) trial (NCT 01470521), which 
was conducted at the Department of Clinical Neurology, University of 
Nottingham.  In this study, 36 patients with multiple sclerosis were 
treated with the hookworm N. americanus (25 larvae applied 
cutaneously per patient) and 36 received placebo (water).  Patients 
meeting McDonald criteria for relapsing and remitting multiple sclerosis 
were included together with secondary multiple sclerosis patients 
(superimposing relapse, subject to specific clinical criteria).  Adequate 
serum samples were available from 51 study participants.  Key study 
timings are shown in Table 4 although it should be noted that this study 
was not a component of the original WIRMS study and serum samples 
from several patients were not available at the specified time points 
because they were used for other purposes or the patients had not 
attended the specified appointments.  The available patient 
demographics are shown in Table 5.
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Table 4. The WIRMS study: timings and key events 
 
Month -¼ 0 ¼ ½ 1 2 3 4 5 6 7 8 9 10 12 
Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
Medical 
assessment and 
informed consent  
               
Blood taken for 
laboratory 
investigations 
               
Randomization to 
helminth or 
placebo 
               
MRI 
 
               
Mebendazole 
 
               
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Table 5.  Patient demographics 
 
Patient 
number 
Age on 
enrolment 
Sex Treatment 
   
Helminth Placebo 
3 49 M Helminth 
 6 37 F Helminth 
 7 27 F 
 
Placebo 
9 37 F 
 
Placebo 
11 42 M 
 
Placebo 
12 57 F Helminth 
 18 45 F Helminth 
 20 35 F 
 
Placebo 
22 36 F Helminth 
 25 54 F Helminth 
 27 49 F Helminth 
 28 59 F 
 
Placebo 
29 36 F Helminth 
 31 47 F 
 
Placebo 
33 48 F Helminth 
 34 32 F 
 
Placebo 
35 56 M 
 
Placebo 
36 46 F Helminth 
 37 59 M Helminth 
 38 29 F 
 
Placebo 
39 52 F Helminth 
 40 41 F 
 
Placebo 
41 32 F Helminth 
 43 39 F Helminth 
 44 62 F 
 
Placebo 
45 40 M 
 
Placebo 
46 46 F Helminth 
 47 56 F Helminth 
 48 46 F 
 
Placebo 
49 32 F 
 
Placebo 
50 46 F 
 
Placebo 
51 32 F Helminth 
 52 54 M 
 
Placebo 
53 39 F Helminth 
 54 63 F 
 
Placebo 
55 60 F Helminth 
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Patient 
number 
Age on 
enrolment 
Sex Treatment 
   Helminth Placebo 
56 59 F  Placebo 
57 53 F Helminth 
 58 34 F Helminth 
 59 37 F 
 
Placebo 
60 54 F 
 
Placebo 
61 64 M 
 
Placebo 
62 29 F 
 
Placebo 
64 34 F Helminth 
 65 41 M Helminth 
 66 40 F Helminth 
 68 37 M Helminth 
 69 41 F 
 
Placebo 
70 53 M Helminth 
 71 46 M 
 
Placebo 
72 54 F 
 
Placebo 
 
 
3.3 Sample collection and storage 
 Serum samples were collected over the period September 2012 
– April 2016.  Approximately, 1.5 ml blood was collected into BD 
Vacutainer tubes (Beckton-Dickinson) and serum separated by 
centrifugation at 1000-1300 relative centrifugal force for 10 minutes.  
Multiple aliquots of the serum samples were stored at -80oC.  
Venepuncture and serum separation was not performed by PACM.  
Serum samples were tested in batches (assay runs) during which time 
they were stored at 2 – 8oC so as to avoid multiple freeze-thawing. 
3.4 Rheumatoid factor absorptions 
 Rheumatoid factor Z200 stock was stood at laboratory 
temperature for one hour and then mixed.  Rheumatoid factor 
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containing assay VCA IgM assay dilution buffer at 20% vol/vol was 
prepared in test tubes by adding 200 μl rheumatoid factor (Z200) to 800 
μl dilution buffer.  A volume of 10 μl of serum sample was then added to 
each tube and the contents vortexed.  The tubes were then stored 
overnight at 6oC +/– 2oC.  They were then stood at laboratory 
temperature for one hour and the contents vortexed before loading onto 
VCA IgM assay plates. 
3.5 ELISA methodology 
 ELISA kits were brought to laboratory temperature by standing 
on the bench for one hour.  Serum samples were diluted 1:100 in kit-
specific dilution buffer by adding 10 μl to 1,000 μl dilution buffer (see 
above for VCA IgM assay).  Ready to use calibrators, control sera and 
diluted test sera were vortexed and designated antigen coated wells of 
each plate were loaded with 100 μl of the appropriate analyte.  Well A1 
was reserved as a blank and loaded with 100 μl dilution buffer, well B1 
was loaded with negative control, wells C1 and D1 were loaded with 
standard/calibrator serum.  Positive control and test sera were loaded 
(100μl/well) into the other test wells.  The plates containing the loaded 
strips were placed in humid chambers and incubated for 60 min (+/- 5 
min) at 37oC (+/- 1oC).  During this time wash buffer was prepared by 
appropriately diluting the 30x wash concentrate in sterile deionized 
water (SDW) eg. 20ml added to 600 ml SDW.  At the end of the 60 min 
incubation the plates were washed using the Demo 8 protocol (wash 
vol. = 300μl/well; no. of washes = 3) of the microplate washer.  After the 
final wash, the plates were tapped against a paper towel (to remove 
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any residual wash buffer) and conjugate added, at 100μl/well, using a 
multichannel pipette.  The plates were then incubated in humid 
chambers for 30 min (+/- 1 min) at 37oC (+/- 1oC).  Conjugate was 
removed by washing using the Demo8 protocol and substrate added to 
all wells at 100μl/well, using a multichannel pipette.  The plates were 
then incubated in humid chambers for a further 30 min (+/- 1 min) at 
37oC (+/- 1oC).  The substrate reaction was then stopped by addition of 
100 μl stopping solution to all wells using a multichannel pipette.  The 
optical densities (ODs) of the reactions were then read, within 20 min, 
using a BioRad microplate reader.  The reader was set at 405 nm with 
a reference wavelength of 650 nm.  
 
3.6 Interpretation and quantification of ELISA results 
 The recorded optical densities were modified by subtraction of 
the blank OD405/650 from the test OD405/650s.  The assay results were 
then validated against the kit-specific validation criteria specified on the 
manufacturer’s quality control certificates.  Subject to passing the 
validation criteria the results were interpreted qualitatively with 
reference to lot specific data supplied on the manufacturer’s quality 
control certificate.  A positive test result confirms that specific antibodies 
have been detected.  For EBV, a panel of antibody results (Table 6) 
has to be interpreted so that the stage of infection (acute/recent, past 
and reactivation) can be assigned.  
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Table 6.  SERION ELISA classic guidelines for the interpretation* 
of EBV serology in immunocompetent individuals. 
Interpretation EBV assay result profile 
EA IgG VCA 
IgM 
VCA 
IgG 
EBNA-1 
IgG 
Not infected or pre-
seroconversion 
Neg Neg Neg Neg 
 
 
 
Acute/recent infection 
Pos Neg Neg Neg 
Neg Pos Neg Neg 
Pos Pos Neg Neg 
Pos Pos Pos Neg 
Pos Neg Pos Neg 
Neg Pos Pos Neg 
Neg Neg Pos Neg 
Past infection Neg Neg Pos Pos 
Neg Neg Neg Pos 
Reactivation Pos++1 Neg Pos++ Pos 
Pos++ Pos Pos++ Pos 
 
*Cut-off criteria of “Neg” (Negative) and “Pos” (Positive) specified in 
manufacturer’s batch specific kit insert.  1Pos++ notation used by 
manufacturer and assumed to be high antibody level, but no defined 
level stipulated. 
3.7 Quantification of assay results 
Modified antibody ODs (blank subtracted) can also be used to 
generate quantitative results due to the incorporation of standard serum 
in each assay run and the provision of a kit, lot-specific standard curve 
(4 parameter, logistic) by the manufacturer.  The standard serum acts 
as a single point calibrator and the calculation of a correction factor (F = 
the manufacturer’s assigned standard OD value/mean assay measured 
run value) enables correction for variation of test OD run values in any 
particular assay run so that they can be interpolated directly from the 
supplied standard curve.  Correction is attained by multiplying the assay 
run test OD values by the calculated correction factor (F).   
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3.8 Quality assurance of assay reproducibility 
 The inclusion of an independent positive control serum in every 
assay run allows within run variation and between run variation to be 
calculated. In every test run, positive control serum was loaded into 
wells E1, F1 and H6 (in some runs G6 loaded, as well).  The positive 
control sera have an assigned target value and target range so assay 
run data can be validated. 
3.9 Statistical Methods 
 Basic data manipulations; for example, calculation of means and 
standard deviations together with graphical presentations were 
performed using Excel 2016.  Statistical analysis was performed using 
Prism 7 software and significance was set at p <0.05.  Details of the 
statistical tests applied are given in the text.  Associations of categorical 
data (eg. sero-prevalence) were tested using Fisher’s exact test 
because of the small sample sizes available.  Associations of non-
paired, continuous data (eg. geometric means) were tested using an 
independent samples t-test and a normal distribution within groups was 
assumed. 
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RESULTS 
4.1 Qualitative and quantitative EBV antibody levels in 
helminth treated (n = 26) and placebo controlled patients (n = 
25). 
 All helminth treated, and placebo controlled multiple sclerosis 
patients tested positive for EBV viral capsid IgG (VCA IgG) and nuclear 
antigen-1 IgG (EBNA-1 IgG).  The antibody levels were very stable over 
the one-year period of the study (Figures 2a and 2b).  A total of 8 
(30.7%) helminth treated patients were EBV early antigen (EA) positive 
compared to 10 (40.0%) placebo controlled patients.  The difference in 
the EBV EA IgG sero-positivity between the two groups was not 
significant (Fisher exact test statistic value = 0.565).  There were a 
number of equivocals in both groups and these have been treated as 
sero-negatives.  It should also be noted that there was some variation 
in the cut-off values between assay runs and these are shown in Table 
7.  
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Figure 2a.  Distribution of EBV VCA IgG levels in all patients (n = 
51) tested 
 
 
 
Box and whisker plot also showing outliers (o) of EBV VCA IgG levels 
of all patients tested for whom sequential sera were available collected 
at visits 1, 6, 12 or 13, and 15.  The edges of the box moving upwards 
represent 25th and 75th percentiles and the internal line the exclusive 
median.  The mean is represented by (x). 
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Figure 2b.  Distribution of EBNA-1 IgG levels in all patients (n = 51) 
tested  
 
 
 
Box and whisker plot also showing outliers (o) of EBNA-1 IgG levels of 
all patients tested for whom sequential sera were available collected at 
visits 1, 6, 12 or 13, and 15.  The edges of the box moving upwards 
represent 25th and 75th percentiles and the internal line the exclusive 
median.  The mean is represented by (x). 
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Table 7.  Variation of cut-off values for EBV EA IgG with assay run 
Assay 
run 
Mean OD405/650 Manufacturer’s stipulated cut-offs OD405/650 
 Standard serum Pos cut-off Equiv range Neg cut-off 
1 0.89 >0.27 0.18 - 0.27 <0.18 
2 0.88 >0.27 0.18 – 0.27 <0.18 
3 1.0 >0.31 0.21 - 0.31 <0.21 
4 0.95 >0.29 0.20 - 0.29 <0.20 
5 0.86 >0.25 0.17 - 0.25 <0.17 
6 0.89 >0.27 0.18 – 0.27 <0.18 
 
 The detection of EBV EA IgG in the presence of EBV VCA IgG 
and EBNA-1 IgG is potentially consistent with virus reactivation (see 
Table 6) so approximately 30% - 40% of patients tested showed 
evidence of EBV reactivation.  In all these cases, the pre-treatment 
serum was EBV EA IgG positive and there was no evidence of a trend 
of increasing EA IgG levels during treatment.  Another marker of EBV 
reactivation is the detection of EBV VCA IgM in patients with evidence 
of past EBV infection (ie. EBNA-1 IgG positive).  One helminth treated 
patient (no. 36) was EBV VCA IgM positive and one placebo-controlled 
patient (no. 48) was EBV VCA IgM positive.  In both cases, the pre-
treatment serum samples were EBV VCA IgM positive and there was 
no significant trend of increasing IgM levels during treatment. 
 Interpolation from the standard curves generated for each assay 
run enabled quantitative antibody levels to be determined.  The 
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manufacturer’s stated limits of quantification for the EBV VCA IgG 
assay were 5 - 200 units/ml (U/ml) and the serum levels detected in the 
multiple sclerosis patients studied ranged from 55 U/ml to >200 U/ml.  
In the helminth treated group, 78.8% serum VCA IgG levels measured 
>200 U/ml and in the placebo controlled group 58.4% of serum VCA 
IgG levels measured >200 units/ml.  A total of 20/26 (76.9%) patients in 
the helminth treated group and 14/25 (58.4%) patients in the placebo 
controlled group commenced the study with EBV VCA IgG levels >200 
units/ml and this difference was not significant (Fisher exact test value 
0.144).  By imputing a level of 201 units/ml to values >200 units/ml, 
geometric mean levels of 182.9 units/ml and 163.5 units/ml were 
generated for helminth treated and placebo controlled groups, 
respectively.  Several sera with EBV VCA IgG levels >200 units/ml 
were subsequently titrated out (see Figure 2a). 
 For the EBNA-1 IgG assay the manufacturer’s stated limits of 
quantification were 1 – 200 U/ml and the serum levels detected in the 
multiple sclerosis patients studied ranged from 9.5 U/ml to >200 U/ml.  
In the helminth treated group 1.7% serum EBNA-1 IgG levels measured 
>200 U/ml and in the placebo controlled group none of the serum 
EBNA-1 IgG levels measured >200 U/ml.  By imputing a level of 201 
U/ml to values >200 U/ml, geometric mean levels of 68.3 U/ml and 68.5 
U/ml were generated for the helminth treated and placebo controlled 
groups, respectively.  The EBNA-1 IgG levels in helminth treated and 
placebo controlled groups were not statistically different (Independent 
samples t-test, t-value = 0.201, p-value = 0.42).  Several sera with 
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EBNA-1 IgG levels >200 units/ml were subsequently titrated out (see 
Figure 2b). 
 The manufacturer’s stated limits of quantification for the EBV EA 
IgG assay were 2 - 400 units/ml (U/ml) and the negative cut-off was 
<10 U/ml, equivocal range was 10 U/ml – 15 U/ml, and positive cut-off 
was >15 U/ml.   In the helminth treated group using the aforementioned 
quantitative cut-offs, 14 patients were EA IgG negative, 3 were 
equivocal, and 8 were EA IgG positive (range 16 U/ml – 65 U/ml).  In 
the placebo controlled group, 12 patients were EA IgG negative, 3 were 
equivocal, and 10 were EA IgG positive (range 16 U/ml – 100 U/ml).  
Generally, EA IgG levels were stable over time, but some patients 
showed more variation than others (Figure 3).  Only one patient (patient 
no 36) in the helminth treated group was EBV VCA IgM positive and 
levels over the period of the study ranged between 40 – 70 U/ml, mean 
52.7 U/ml.  Similarly, only one patient (patient no 48) in the placebo 
controlled group was EBV VCA IgM positive and levels over the period 
of the study ranged between 25 – 30 U/ml, mean 27 U/ml.  Both 
patients 36 and 48 were EA IgG positive with levels ranging over the 
period of the study of 13 – 16 U/ml and 26 U/ml, respectively.   
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Figure 3.  EBV early antigen levels over time in (a) helminth 
treated, and (b) placebo controlled patients  
(a) Helminth treated patients 
 
(b)  Placebo controlled patients 
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4.2 Qualitative and quantitative CMV and VZV antibody levels 
in helminth treated (n = 26) and placebo controlled patients (n 
= 25). 
A total of 13 (50%) helminth treated patients and 4 (16.0%) 
placebo control patients were positive for CMV IgG.  The difference in 
the CMV IgG sero-positivity between the two groups was significant 
(Fisher exact test value = 0.016).   Generally, the CMV IgG levels were 
stable over the one-year period of the study (Figure 4a); however, in 
one CMV IgG negative patient (no. 45) there was a transient 
seroconversion at visit 8.  The visit 8 test result was reproducible and 
on further investigation of clinical history (eg. administration of blood 
products) there was no explanation for this finding.  At visit 10, two 
months later, the patient had reverted to being CMV IgG negative.  All 
samples tested were VZV IgG positive and the antibody levels detected 
were very stable over the period of the study (Figure 4b) even in the 
patient (no. 45) with the transient CMV IgG seroconversion (VZV IgG 
OD405/650s were 1.86, 1.86 and 1.87 at visits 6, 8, and 10, respectively).  
The absence of a spike in VZV IgG levels at visit 8 for patient no. 45 
would mitigate against the CMV IgG spike at the same visit been a 
false-positive reaction and measurement of CMV DNA may have 
proved informative; however, it was not possible to undertake this 
investigation. 
 The manufacturer’s stated limits of quantification for the CMV 
IgG assay were 10 - 2000 PEI (Paul Ehrlich Institute) units/ml (U/ml) 
and the negative cut-off was <25 PEI-U/ml, equivocal range was 25 
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PEI-U/ml – 40 PEI-U/ml, and positive cut-off was >40 PEI-U/ml.   In the 
helminth treated group using these cut-offs, 13 patients were CMV IgG 
negative and 13 were CMV IgG positive (range 120 PEI-U/ml – 1700 
PEI-U/ml; geometric mean = 428 PEI-U/ml).  In the placebo controlled 
group, 21 patients were CMV IgG negative and 4 were CMV IgG 
positive (range 85 PEI-U/ml – 1400 PEI-U/ml; geometric mean = 321 
PEI-U/ml).  Generally, CMV IgG levels were stable over time; however, 
in one patient (no. 45) CMV IgG levels were <10 PEI-U/ml at visits 1 
and 6, then increased to 750 PEI-U/ml at visit 8, and reverted to <10 
PEI-U/ml at visits 10, 12, 13 and 15. 
 For the VZV IgG EIA the manufacturer’s stated limits of 
quantification were 15 – 2000 mIU/ml and the negative cut-off was <50 
mIU/ml, equivocal range was 50 mIU/ml – 100 mIU/ml, and positive cut-
off was >100 mIU/ml.  The range of VZV IgG levels detected was 220 
mIU/ml - >2000 mIU/ml in both the helminth treated and placebo 
controlled groups.  By imputing a level of 2001 mIU/ml to values >2000 
mIU/ml, geometric mean levels of 1098 mIU/ml and 1200 mIU/ml were 
generated for the helminth treated and placebo controlled groups, 
respectively.   The VZV IgG levels in helminth treated and placebo 
controlled groups were statistically different (Independent samples t-
test, t-value = -2.27, p-value = 0.011).  Several sera with VZV IgG 
levels >2000 mIU/ml were subsequently titrated out (see Figure 4b). 
Table 8 provides a summary of sero-prevalence findings for the virus 
markers tested. 
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Table 8.  Summary of sero-prevalence findings for helminth 
treated (n = 26) and placebo controlled (n = 25) patients  
 
Virus marker Rate of antibody positives (%) 
Helminth treated Placebo controlled 
EBV VCA IgG 100% 100% 
EBV VCA IgM 3.8% 4.0% 
EBNA-1 IgG 100% 100% 
EBV EA IgG 30.7% 40% 
CMV IgG 50% 16% 
VZV IgG 100% 100% 
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Figure 4a.  Distribution of CMV IgG levels in all patients (n = 51) 
tested 
 
 
 
Box and whisker plot also showing outliers (o) of CMV IgG levels of all 
patients tested for whom sequential sera were available collected at 
visits 1, 6, 12 or 13, and 15.  The edges of the box moving upwards 
represent 25th and 75th percentiles and the internal line the exclusive 
median.  The mean is represented by (x). 
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Figure 4b.  Distribution of VZV IgG levels in all patients (n = 51) 
tested  
 
 
Box and whisker plot also showing outliers (o) of VZV IgG levels of all 
patients tested for whom sequential sera were available collected at 
visits 1, 6, 12 or 13, and 15.  The edges of the box moving upwards 
represent 25th and 75th percentiles and the internal line the exclusive 
median.  The mean is represented by (x). 
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4.3 Determination of assay variability 
4.3.1 Within run variability 
 In all assay runs (Table 9) there was an average coefficient of 
variation (COV) of 4.62% (range 0% - 12.3%) in within plate internal 
quality control serum quantitative antibody levels.   
Table 9. Within (intra) assay coefficient of variation (%) of internal 
quality control serum levels 
Assay 
run 
EA IgG 
BC1363G 
%COV/run 
VCA IgG 
BC1361G 
%COV/run 
VCA IgM 
BC1361M 
%COV/run 
EBNA-1 IgG 
BC1362G 
%COV/run 
CMV IgG 
BC109G 
%COVrun 
VZV IgG 
BC104G 
%COV/run 
1 0% 0% 6.3% 2.06% 5.8% 10.9% 
2 0% 3.49% 8.2% 3.7% 3.7% 10.4% 
3 7.9% 12.0% 12.35% 3.9% 0% 7.18% 
4 3.48% 0% 3.17% 10.1% 10.5% 2.98% 
5 10.8% 0% 8.24% 3.27% 3.38% 0% 
6 3.92% 0% 8.66% 0% 0% 0% 
 
4.3.2 Between run variability 
 For the different assays used, the between run COV was no 
more than 12.0% (range 3.71% - 12.0%; mean = 6.35%) as determined 
from the mean quantitative values/run of the internal quality control sera 
(Table 10).
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Table 10. Mean internal quality control serum levels per assay run 
  
Assay 
run 
EA IgG 
BC1363G 
Mean U/ml 
VCA IgG 
BC1361G 
Mean U/ml 
VCA IgM 
BC1361M 
Mean U/ml 
EBNA-1 IgG 
BC1362G 
Mean U/ml 
CMV IgG 
BC109G 
Mean PEI-
U/ml 
VZV IgG 
BC104G 
Mean 
mIU/ml 
1 32 80 66 27.6 150 314 
2 32 82.5 70 31 155 330 
3 31.6 86.6 56 29.3 140 320 
4 33 80 78.7 29.5 142.5 335 
5 32 100 70 30.5 147.5 300 
6 29.3 100 66.6 30 150 320 
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DISCUSSION 
5.1 Putting the results in context 
5.1.1 Defining the patient cohort 
 A major determinant of the outcome of any clinical trial is the 
patient population studied (227).  In particular, the clinical phenotypes 
recruited may differ significantly in underlying pathology and the 
capacity to respond to treatment.  These issues are highly relevant for 
multiple sclerosis and in 1996 standardized definitions for the most 
common clinical courses of patients with multiple sclerosis were 
published (228).  In total, four multiple sclerosis clinical courses were 
identified – relapsing-remitting (RRMS), secondary progressive 
(SPMS), primary progressive (PPMS), and progressive-relapsing MS 
(PRMS).  These standards were revised in 2013 (229) and although the 
broad classifications remain there is more emphasis on assessing 
disease activity and application of imaging together with relevant 
laboratory data.  In the WIRMS study, which commenced 2012 the 
majority of patients were RRMS with some SPMS; however, for the 
purposes of the (our) study reported here the breakdown by clinical 
phenotype is not yet available.   
5.1.2 How does helminth therapy impact upon the mechanism of 
multiple sclerosis and is there a rationale for predicting herpes virus 
reactivation? 
 The mechanism of disease in RRMS is predominantly 
inflammatory with the production of focal inflammatory lesions 
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characterized by perivenular accumulation of lymphocytes, disruption of 
the blood-brain barrier, compromise of regulatory cell activity, 
demyelination, and acute axonal transection (22, 230).  In progressive 
multiple sclerosis (PMS) there is a mechanistic shift from focal 
inflammatory pathology towards more diffuse immunological events and 
domination by incompletely understood neurodegenerative 
mechanisms with the consequence that many treatments for RRMS 
have little efficacy on PMS (95, 231). 
 Until recently, the view prevailed that multiple sclerosis was 
primarily an autoimmune disease driven by T cell dysfunction (45, 232).  
For instance, evidence has been presented in mice that following EAE 
induction the immune response is dominated by interferon-γ producing 
TH1 cells capable of inducing EAE when transferred to syngeneic 
recipients (233).  More recently, the classical separation (234) of TH cell 
populations into type 1 and 2 populations has been superseded by 
recognition of the existence of another TH cell population – TH17 (235).  
Just as γ-interferon is the signature effector cytokine of TH1 
lymphocytes, interleukin 17A (IL-17A) is the signature effector cytokine 
of TH17 lymphocytes.  A significant function of IL-17A is the induction of 
colony stimulating factors (eg. GM-CSF).  Neutralization of IL-17, or IL-
17 deficiency, in mice have been shown to manifest resistance to the 
induction of EAE (236, 237).  Experimental studies have shown that 
TH17 lymphocytes display considerable plasticity dependent on the 
inflammatory environment and that the nature of the interplay between 
TH1, TH17 and other TH lymphocyte populations remains to be fully 
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determined (238).  For instance, GM-CSF may be produced by TH1 or 
TH17 populations or other independent populations of TH cells which 
are neither TH1 or TH17. 
 Regulatory T cells (Tregs) may be thymically derived (natural Treg - 
nTreg) or peripherally generated (adaptive/inducible Treg - iTreg) and a 
variety of population subsets are to be found all with the transcriptional 
regulator Forkhead box protein 3 (FoxP3).  A key function of Tregs is that 
they act as a critical control point for the maintenance of self-tolerance; 
however, they possess other important functions such as the control of 
inflammatory processes (239).  There is abundant evidence that Tregs 
modulate CNS inflammation and play a key role in the development 
and progression of autoimmune diseases (240).  It is now well 
established that defective function of Tregs is a component of RRMS as 
evidenced by reduced suppressive capacity compared to healthy 
controls (241). The reduction of Tregs suppressive capacity in RRMS 
patients has been shown to be reversible following treatment with 
interferon β1a (242). 
 The presence of oligoclonal banding in the CSF is highly 
associated with multiple sclerosis and has been used as a biomarker 
for the disease (243).  The presence of such bands in CSF reflects 
intrathecal oligoclonal IgG synthesis; however, this may be non-specific 
for multiple sclerosis (244).  B lymphocytes play a major role at the site 
of inflammation through the release of cytokines and B regulatory cell 
function is important in determining the extent of pro-inflammatory 
activity (245).  The use of B cell depletion by treatment with B cell 
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specific depleting monoclonals eg. rituximab) has been shown to be 
beneficial in the treatment of multiple sclerosis (246).   There is a 
considerable need to gain greater knowledge of the role of effector and 
regulatory B cells in multiple sclerosis (247) and a recent finding of 
interest is that B cells from patients with multiple sclerosis induce, 
cytokine independent, apoptotic pathways resulting in neuron 
cytotoxicity (248). 
 It is highly evident that a diversity of immune cell types and 
processes contribute to multiple sclerosis (249) and it cannot be 
considered solely as a disease mediated by TH1 mechanisms.  The 
same can be said of the immune response to helminth infections in that 
they do not just elicit TH2 responses (126).  There is significant 
evidence, which has been reviewed in section 1.3.3 for the general 
applicability of helminth therapy in multiple sclerosis.  In the context of 
the WIRMS (our) study there are very limited external data on how the 
therapeutic dose of helminth used will impact on relevant immunological 
pathways.  If there is an effect, it remains to be determined over what 
time it may generate, and if it is compensated for by modification, or 
plasticity, of affected immune pathways.  Consequently, there is a very 
limited database, which can be used to predict an effect of helminth 
therapy on herpes virus reactivation as a result of the specific 
conditions used in the WIRMS study.  The findings reported in our study 
of a UK population may not be translatable to, for example, populations 
with natural helminth infection.    
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5.2 Assessment of the herpes virus antibody levels detected 
5.2.1 The significance of the EBV virus antibody levels detected 
 All patients (n = 51) tested showed evidence of past EBV 
infection and this confirms previous reports of virtually 100% sero-
prevalence of EBV VCA IgG and EBNA-1 IgG in patients with multiple 
sclerosis (181, 188).  No significant difference was found between the 
rate (30.7%) of EBV EA IgG sero-positivity in helminth treated patients 
(n = 26) compared to the rate (40.0%) of EBV EA IgG sero-positivity in 
placebo controlled patients (n = 25).  Previous studies (250) have 
reported similar rates (36% versus 41%) of EBV EA IgG sero-positivity 
in multiple sclerosis patients compared to healthy controls.  Other 
studies (189, 199) have reported an increased sero-prevalence of EBV 
EA IgG in patients with multiple sclerosis.  The detection of EBV EA IgG 
is associated with acute infection or virus reactivation; however, care is 
needed in making either inference as EBV EA IgG is also detected in 
20% – 30% healthy controls and can persist for years after a primary 
infection (251).  In all our cases, the pre-treatment serum was EBV EA 
IgG positive and there was no evidence of a trend of increasing EA IgG 
levels during treatment.  The detection of EBV VCA IgM is principally 
associated with primary infection (172) and it is infrequently detected in 
cases of reactivation (252).  EBV VCA IgM was detected in only one 
helminth treated patient and a placebo controlled patient.  In both 
cases, the pre-treatment serum samples were EBV VCA IgM positive 
and there was no significant trend of increasing IgM levels during 
treatment.  These data lead to the conclusion that helminth treatment 
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under the conditions of the WIRMS study was not associated with EBV 
reactivation.  A significant number of patients (30% - 40%) appeared to 
be in a state of persistent EBV reactivation and this finding has been 
reported in other studies (195, 253). 
 There have been conflicting reports linking clinical relapse or 
disease progression with EBV infection/reactivation.  For instance, 
Farrell and colleagues (190) who investigated 100 subjects over a five-
year period suggested, on the basis of elevated EBNA-1 IgG titres, that 
there was an association between EBV infection and multiple sclerosis 
disease activity.  Unfortunately, EBV EA IgG levels were not examined 
in this study and the variability of the commercial assay used for EBNA-
1 IgG quantitation was not given.  In our study, no significant difference 
in EBNA-1 IgG levels was found between helminth-treated and 
placebo-controlled groups.  Limitations of both studies are that the 
EBNA-1 IgG levels obtained are not comparable and EBNA-1 IgG 
levels were not determined in appropriate populations to determine 
“normal” ranges.  In another study, by Buljevac and colleagues (195), 
73 RRMS patients were followed for an average of 1.7 years and no 
association was found between increased clinical disease activity and 
serological evidence of EBV reactivation.  There are similarities in the 
findings of this study and our study; for example, EBV EA IgG levels 
were stable over time and EBV VCA IgM was detected in only three 
cases.  At the time of submission an analysis of clinical disease activity 
in the WIRMS study patients is not available so no comment can be 
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made regarding clinical disease activity and the EBV antibody levels 
detected in our study.       
5.2.2 The significance of the CMV and VZV virus antibody levels 
detected 
 A total of 13 (50%) helminth treated patients (n = 26) and 4 
(16.0%) placebo controlled patients (n = 25) were positive for CMV IgG.  
The difference in the CMV IgG sero-positivity between the two groups 
was significant (Fisher exact test value = 0.016).   Generally, the CMV 
IgG levels were stable over the one-year period of the study.  The 
disparity between CMV IgG sero-prevalence in helminth treated 
patients compared to placebo controlled patients raises the question of 
recruitment bias due to unknown factors.  In studies (195) in which 
CMV IgG seroprevalence has been compared between multiple 
sclerosis patients and healthy controls no disparity has been observed.  
In an urban region of the UK, significant disparities in CMV IgG sero-
prevalence have been observed between women of different ethnicity 
(254) and this may be a factor contributing to the disparity of CMV IgG 
sero-prevalence between groups observed in our study.  Population 
CMV IgG sero-prevalences of 41.5% - 76.7% have been reported in 
Western European countries (255) so the detected sero-prevalence of 
16.0% in our placebo controlled patient group is highly atypical. 
 There have been conflicting reports regarding the significance of 
CMV infection in multiple sclerosis patients.  Horakova and colleagues 
(256) have reported that CMV positivity increases the likelihood of 
  72 
relapses in clinically isolated syndrome (CIS) patients.  The same group 
has also shown that humoral immunity to CMV is associated with brain 
atrophy in CIS patients treated with interferon-β (218).  It has been 
suggested (219) that cytomegalovirus infection causes chronic 
activation of the immune system and that cytotoxic and pro-
inflammatory CD4+CD28nullT cells are only present in CMV seropositive    
candidates, which promote autoimmune mediated neuroinflammation. 
Conversely, there have been other reports that attribute to CMV 
positivity a disease-limiting role (257) or negative association with the 
risk of disease manifestation (217).  Several mechanisms have been 
proposed for this variety of effects of CMV infection in relation to 
multiple sclerosis (258). 
 In our study, all patients tested (n = 51) were VZV IgG positive 
and there was a statistically significant difference in antibody levels 
between helminth treated (geometric mean = 1098 mIU/ml) and 
placebo controlled groups (geometric mean = 1200 mIU/ml).  There 
have been reports (259, 260) of higher rates of VZV IgG sero-
prevalence or prior varicella/herpes zoster in patients with multiple 
sclerosis compared to the general population.  Unfortunately, in our 
study a control population has not been tested so no comparisons of 
VZV IgG sero-prevalence/antibody levels can be made.  In the 
laboratory, VZV reactivation (shingles) is best determined by detecting 
a significant increase in VZV IgG levels or through viral load 
measurements (261) as detection of VZV IgM is unreliable due to the 
lack of sensitivity of routinely available assays (262, 263).  In our study, 
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no serological evidence of VZV reactivation was seen in any of the 
patients tested.  The apparent difference in VZV IgG levels between 
helminth treated and placebo controlled patients may reflect an 
unknown selection bias and when the WIRMS study clinical data is fully 
available can be explored further. 
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5.3 Conclusions 
 In this study, the herpes virus antibody levels (EBV EBNA-1 IgG, 
EBV VCA IgG, EBV VCA IgM, EBV EA IgG, CMV IgG, VZV IgG) in 
helminth treated and placebo controlled multiple sclerosis patients have 
been monitored over a period of time with the following findings. 
1. All individuals tested (n = 51) showed evidence of past EBV infection. 
2. Compared to animal studies (130, 225) no evidence of EBV 
reactivation in humans therapeutically infected with a low number of 
helminth ova has been found. 
3. Over a period of one-year EBNA-1 IgG, EBV VCA IgG, and EBV 
VCA IgM antibody levels were stable. 
4. EBV EA IgG was detected in 30.7% helminth treated patients (n = 
26) compared to 40.0% placebo controlled patients (n = 25).  The 
difference was not significant (p<0.05).  Levels were stable throughout 
the period of the study including pre-treatment and post-treatment 
phases.  The significance of this finding warrants confirmation by further 
investigations. 
5. CMV IgG and VZV IgG levels were stable throughout the period of 
the study and there was no serological evidence of CMV or VZV 
reactivation. 
6. CMV IgG was detected in 50% helminth treated compared to 16.0% 
placebo controlled patients.  This difference was significant (p<0.05) 
and raises the issue of recruitment bias due to unknown factors. 
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7. VZV IgG was detected in all patients tested and there was a 
significant (p<0.05) difference in levels between helminth treated and 
placebo controlled groups.  The antibody levels were very stable 
throughout the period of sampling, so the disparity represents potential 
recruitment bias. 
8. Vaccines are either available (eg. VZV) or under development (CMV, 
EBV) for the human herpesviruses tested in our study.  Likewise, a 
number of new therapeutic agents (eg. alemtuzumab) are entering 
clinical use for which herpes virus reactivations have been recorded.  
Our findings will help inform their current or future use.  
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5.4 Future work 
 The collection of samples from the WIRMS study with associated 
clinical data represents a high-value, scientific resource.  Because sera 
were multiple aliquotted at the time of sample processing there is the 
facility to reduce freeze-thawing episodes of samples to a minimum.  
Some additional laboratory testing could help resolve several issues 
raised in the Discussion, as follows. 
1.  Testing a control group of samples from a “general” or non-multiple 
sclerosis cohort using the same methodology would enable 
comparative sero-prevalences of herpes virus antibodies to be 
determined.  Such data would either support or refute previously 
published findings of associations of herpes virus infections with the 
development of multiple sclerosis or aspects of multiple sclerosis such 
as disease severity. 
2. Full quantitation of antibody levels by testing higher dilutions of sera 
to determine quantitative end-points would enable valid comparisons of 
quantitative antibody levels to be made with clinical or radiologically 
determined disease activity. 
3. The utility of EBV VCA EA IgG detection as a marker of virus 
reactivation needs to be assessed further.  Do patients with evidence of 
persistent EBV reactivation by this assay have adverse clinical 
outcomes compared to controls?  Confirmatory serological testing and 
viral load data would be useful for this group. 
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4. The findings following CMV IgG testing are remarkable.  A greater 
understanding of the role of CMV infection is much needed, as there is 
the possibility of therapeutic intervention, if necessary.  In view of the 
conflicting findings from published reports further studies at the cellular 
level are required to increase our understanding of the interactions of 
the immune systems of multiple sclerosis patients at different stages of 
disease with this virus. 
5. Sero-prevalence and quantitative antibody levels should be 
determined for the other human herpes viruses (eg HHV-1/2 and HHV-
6/7) not tested in this study.  Herpes Simplex viruses 1 and 2 (HHV-1/2) 
are very closely related herpesviruses belonging to the genus 
Simplexvirus and like VZV are classified in the subfamily 
Alphaherpesvirinae (264).  Similar to VZV, HHV1/2 viruses establish 
latency in sensory neurons; however, they adopt very different modes 
of pathogenesis and have significantly different clinical manifestations 
and aetiologies (265).  Historically, HHV-1 infection was associated with 
herpes gingivostomatitis and HHV-2 infection was associated with 
genital herpes, but these boundaries are now blurred as a 
consequence of changes in sexual behaviour.  Both HHV-1/2 are 
significant causes of neurological infections and show different 
characteristic clinical presentations (266).  HHV-1 is a major cause of 
sporadic encephalitis in immunocompetent individuals while HHV-2 is 
associated with aseptic meningitis in adults.  In immunosuppressed 
patients and the neonate, infection by either virus can disseminate with 
significant morbidity and mortality.  Diagnosis of infection is by nucleic 
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acid detection of virus DNA following polymerase chain reaction using 
appropriate samples.  For suspected encephalitis, it is recommended 
that serum and CSF samples be analysed – CSF should be tested for 
virus DNA and both samples tested for antibody to determine 
intrathecal production (267).  Unfortunately, for this study serum 
samples only were available for testing so only limited data would be 
obtained if HHV-1/2 testing had been undertaken.  Furthermore, 
although commercially available type specific serological tests are 
available for the detection of HHV-1/2 antibodies obtaining reliable data 
for HHV-2 is subject to a number of technical limitations (268).  These 
include significant numbers of false-positive results in low prevalence 
populations, delayed seroconversion, sero-reversion (269).  Any 
meaningful study of HHV-1/2 would need to address the 
aforementioned issues.  Previous studies (199, 214, 216) have failed to 
show an association of HHV-1/2 antibodies with multiple sclerosis. 
 There are two variants of human herpesvirus 6 (HHV-6A and 
HHV-6B) and both these and human herpesvirus 7 (HHV-7) can be 
cultured from peripheral blood mononuclear cells and are classified in 
the subfamily Betaherpesvirinae.  They are associated with the 
childhood disease roseola (exanthem subitem) to differing extents 
(mainly HHV-6B).  Seizures and severe encephalitis have been linked 
to primary infection and reactivation in immunocompromised patients 
respectively and it has been proposed to have an association with 
multiple sclerosis (270).  Antigenic cross-reactivity between HHV-6 and 
HHV-7 limits the usefulness of serological assays (271) so, although it 
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would have been interesting to investigate HHV-6 antibody levels in the 
WIRMS sera any data obtained would be compromised.  Finally, HHV-8 
is the most recently discovered of the human herpesviruses (272) and 
there is little reason to consider a potential association of this 
herpesvirus with multiple sclerosis (273).  
6. Human herpesvirus infections may act as markers (see Discussion) 
for risk of multiple sclerosis and severity of disease.  It would be 
interesting to see whether clinically isolated syndrome patients show 
similar serological characteristics. 
7. There has been considerable interest in the influence of host 
microbiome in the generation of disease and, within this, the host 
virome may play a very significant role.  We should endeavour to add to 
this body of knowledge. 
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7.0 APPENDICES 
 
7.1  Qualitative EBV antibody levels in helminth treated patients  
 
OD405/650 interpn OD 405/650 interpn OD405/650 interpn OD405/650 interpn 
Sample/visit EBV EA IgG 
 
EBV VCA 
IgM 
 
EBV VCA 
IgG 
 
EBNA 1 
IgG 
 Patient no 3 
        WD003 v1 0.04 Neg 0.07 Neg 1.6 Pos 1.6 Pos 
WD003 v8 0.04 Neg 0.08 Neg 1.6 Pos 1.6 Pos 
WD003 v14 0.04 Neg 0.07 Neg 1.5 Pos 1.6 Pos 
WD003 v15 0.04 Neg 0.07 Neg 1.6 Pos 1.6 Pos 
Patient no 6 
        SN 006 v1 0.43 Pos 0.1 Neg 1.9 Pos 1.6 Pos 
SN006 v12 0.42 Pos 0.1 Neg 1.9 Pos 1.6 Pos 
SN006 v15 0.43 Pos 0.11 Neg 2 Pos 1.7 Pos 
Patient no 12 
        JH014 v1 0.33 Pos  0.04 neg 1.93 pos 1.93 pos 
JH014 v8 0.26 Pos  0.04 neg 1.93 pos 1.94 pos 
JH014 v10 0.3 Pos  0.04 neg 2 pos 2 pos 
JH014 v12 0.36 Pos  0.05 neg 2 pos 2 pos 
JH014 v14 0.37 Pos  0.06 neg 2 pos 2 pos 
JH014 v15 0.34 Pos  0.05 neg 1.99 pos 2 pos 
Patient no 18 
        DC018 v1 0.19 neg 0.04 neg 1.41 pos 2 pos 
DC018 v6 0.16 neg 0.04 neg 1.27 pos 2 pos 
DC018 v12 0.15 neg 0.04 neg 1.26 pos 2 pos 
DC018 v15 0.14 neg 0.03 neg 1.31 pos 1.9 pos 
Patient no 22 
        RY022 v1 0.26 equiv 0.12 neg 1.45 pos 1.32 pos 
RY022 v6 0.22 equiv 0.13 neg 1.4 pos 0.91 pos 
RY022 v12 0.14 neg 0.09 neg 1.38 pos 0.83 pos 
RY022 v15 0.2 neg 0.1 neg 1.46 pos 0.9 pos 
Patient no 25 
        TC025 scr 0.53 pos 0.1 neg 1.56 pos 1.3 pos 
TC025 v6 0.5 pos 0.11 neg 1.48 pos 1.27 pos 
TC025 v8 0.53 pos 0.12 neg 1.59 pos 1.35 pos 
TC025 v10 0.51 pos 0.13 neg 1.64 pos 1.36 pos 
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OD405/650 interpn OD 405/650 interpn OD405/650 interpn OD405/650 interpn 
Sample/visit EBV EA IgG 
 
EBV VCA 
IgM 
 
EBV VCA 
IgG 
 
EBNA 1 
IgG 
 TC025 v12 0.48 pos 0.11 neg 1.64 pos 1.19 pos 
TC025 v13 0.49 pos 0.11 neg 1.61 pos 1.25 pos 
TC025 v15 0.46 pos 0.1 neg 1.51 pos 1.23 pos 
Patient no 27 
        KB028 v1 0.12 neg 0.45 equiv 1.4 pos 1.74 pos 
KB028 v6 0.13 neg 0.49 equiv 1.44 pos 1.87 pos 
KB028 v12 0.08 neg 0.44 equiv 1.25 pos 1.76 pos 
KB028 v15 0.08 neg 0.46 equiv 1.32 pos 1.62 pos 
Patient no 29 
        RJ029 v1 0.1 neg 0.14 neg 1.55 pos 1.4 pos 
RJ029 v6 0.09 neg 0.18 neg 1.49 pos 1.39 pos 
RJ029 v12 0.09 neg 0.45 equiv 1.62 pos 1.43 pos 
RJ029 v15 0.1 neg 0.15 neg 1.58 pos 1.36 pos 
Patient no 33 
        EW027 v1 0.08 neg 0.51 equiv 1.23 pos 1.74 pos 
EW027 v6 0.07 neg 0.46 equiv 1.12 pos 1.72 pos 
EW027 v12 0.08 neg 0.49 equiv 1.23 pos 1.75 pos 
EW027 v15 0.08 neg 0.52 equiv 1.26 pos 1.77 pos 
Patient no 36 
        HW036 v1 0.3 equiv 1.37 pos 0.85 pos 2 pos 
HW036 v6 0.27 equiv 1.79 pos 0.77 pos 2 pos 
HW036 v12 0.32 pos 1.28 pos 0.99 pos 2.2 pos 
HW036 v15 0.32 pos 1.54 pos 0.98 pos 2.2 pos 
Patient no 37 
        SD037 v1 0.11 neg 0.05 neg 1.41 pos 1.5 pos 
SD037 v6 0.11 neg 0.05 neg 1.46 pos 1.5 pos 
SD037 v12 0.11 neg 0.05 neg 1.38 pos 1.4 pos 
SD037 v15 0.11 neg 0.04 neg 1.42 pos 1.4 pos 
Patient no 39 
        RB039 v1 0.95 Pos 0.093 Neg 1.45 Pos 1.36 Pos 
RB039 v6 0.85 Pos 0.09 Neg 1.42 Pos 1.32 Pos 
RB039 v12 0.89 Pos 0.14 Neg 1.44 Pos 1.33 Pos 
RB039 v15 0.88 Pos 0.45 equiv 1.43 Pos 1.38 Pos 
Patient no 41 
        JR041 v1 0.18 neg 0.09 neg 1.55 pos 2 pos 
JR041 v6 0.17 neg 0.08 neg 1.53 pos 2 pos 
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OD405/650 interpn OD 405/650 interpn OD405/650 interpn OD405/650 interpn 
Sample/visit EBV EA IgG 
 
EBV VCA 
IgM 
 
EBV VCA 
IgG 
 
EBNA 1 
IgG 
 JR041 v12 0.16 neg 0.08 neg 1.51 pos 1.9 pos 
JR041 v15 0.17 neg 0.08 neg 1.58 pos 2 pos 
Patient no 43 
        LS043 v1 0.18 Neg 0.1 Neg 1 Pos 1.66 Pos 
LS043 v6 0.18 Neg 0.11 Neg 1 Pos 1.57 Pos 
LS043 v12 0.19 Neg 0.1 Neg 1 Pos 1.6 Pos 
LS043 v15 0.19 Neg 0.1 Neg 1 Pos 1.66 Pos 
Patient no 46 
        AW045 v1 0.18 Equiv 0.04 Neg 1.3 Pos 1.7 Pos 
AW045 v6 0.23 Equiv 0.05 Neg 1.3 Pos 1.7 Pos 
AW045 v12 0.21 Equiv 0.04 Neg 1.3 Pos 1.7 Pos 
AW045 v15 0.21 Equiv 0.04 Neg 1.4 Pos 1.7 Pos 
Patient no 47 
        SM046 v1 0.1 Neg 0.03 Neg 1.74 Pos 1.8 Pos 
SM046 v6 0.1 Neg 0.03 Neg 1.77 Pos 1.81 Pos 
SM046 v12 0.11 Neg 0.03 Neg 1.78 Pos 1.85 Pos 
SM046 v15 0.1 Neg 0.02 Neg 1.68 Pos 1.75 Pos 
Patient no 51 
        LB051 v1 0.3 Pos 0.4 Equiv 1.9 Pos 1.8 Pos 
LB051 v6 0.33 Pos 0.38 Equiv 1.9 Pos 1.8 Pos 
LB051 v12 0.3 Pos 0.37 Equiv 1.8 Pos 1.7 Pos 
LB051 v15 0.32 Pos 0.36 Equiv 1.8 Pos 1.7 Pos 
Patient no 53 
        SWC053 v1 0.07 Neg 0.07 Neg 1.5 Pos 1.7 Pos 
SWC053 v6 0.07 Neg 0.08 Neg 1.5 Pos 1.6 Pos 
SWC053 v12 0.07 Neg 0.07 Neg 1.5 Pos 1.7 Pos 
SWC053 v15 0.07 Neg 0.08 Neg 1.5 Pos 1.6 Pos 
Patient no 55 
        AS055 v1 0.48 Pos  0.02 neg 1.96 pos 1.85 pos 
AS055 v5 0.5 Pos  0.01 neg 2 pos 1.94 pos 
AS055 v6 0.45 Pos  0.01 neg 2.1 pos 1.91 pos 
AS055 v8 0.42 Pos  0.01 neg 2 pos 1.82 pos 
AS055 v10 0.398 Pos  0.01 neg 1.95 pos 1.77 pos 
AS055 v12 0.392 Pos  0.01 neg 1.96 pos 1.8 pos 
AS055 v13 0.33 Pos  0.01 neg 1.96 pos 1.77 pos 
AS055 v15 0.378 Pos  0.01 neg 1.93 pos 1.78 pos 
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 Patient no 57 
        KB057 v1 0.11 Neg 0.2 Neg 1.4 Pos 1.7 Pos 
KB057 v6 0.11 Neg 0.19 Neg 1.4 Pos 1.8 Pos 
KB057 v12 0.09 Neg 0.19 Neg 1.4 Pos 1.7 Pos 
KB057 v15 0.1 Neg 0.17 Neg 1.4 Pos 1.8 Pos 
Patient no 58 
        EL059 v1 0.13 Neg 0.14 Neg 1.7 Pos 1.6 Pos 
EL059 v6 0.14 Neg 0.13 Neg 1.8 Pos 1.7 Pos 
EL059 v12 0.14 Neg 0.13 Neg 1.8 Pos 1.7 Pos 
EL059 v15 0.13 Neg 0.12 Neg 1.7 Pos 1.7 Pos 
Patient no 64 
        TR065 v1 0.12 neg 0.2 neg 2 pos 1.97 pos 
TR065 v5 0.11 neg 0.2 neg 2 pos 2 pos 
TR065 v6 0.12 neg 0.19 neg 2.1 pos 1.98 pos 
TR065 v7 0.11 neg 0.2 neg 2 pos 1.92 pos 
TR065 v8 0.11 neg 0.2 neg 2 pos 1.84 pos 
TR065 v10 0.11 neg 0.17 neg 2 pos 1.88 pos 
TR065 v12 0.13 neg 0.18 neg 2 pos 1.86 pos 
TR065 v13 0.14 neg 0.18 neg 2 pos 1.87 pos 
TR065 v15 0.12 neg 0.17 neg 2 pos 1.88 pos 
Patient no 65 
        MF066 v1 0.06 Neg 0.03 Neg 1.7 Pos 1.7 Pos 
MF066 v6 0.06 Neg 0.04 Neg 1.8 Pos 1.7 Pos 
MF066 v12 0.06 Neg 0.04 Neg 1.8 Pos 1.7 Pos 
MF066 v15 0.06 Neg 0.03 Neg 1.7 Pos 1.7 Pos 
Patient no 66 
        KW067 v1 0.2 Equiv 0.2 Neg 1.2 Pos 1.6 Pos 
KW067 v6 0.2 Equiv 0.17 Neg 1.1 Pos 1.6 Pos 
KW067 v12 0.17 Neg 0.16 Neg 1.2 Pos 1.5 Pos 
KW067 v15 0.22 Equiv 0.17 Neg 1.2 Pos 1.6 Pos 
Patient no 68 
        AD068 v1 0.1 Neg 0.04 Neg 1.9 Pos 1.7 Pos 
AD068 v6 0.11 Neg 0.05 Neg 2 Pos 1.8 Pos 
AD068 v12 0.1 Neg 0.06 Neg 1.9 Pos 1.9 Pos 
AD068 v15 0.09 Neg 0.05 Neg 1.9 Pos 1.8 Pos 
Patient no 70 
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IgM 
 
EBV VCA 
IgG 
 
EBNA 1 
IgG 
 PC070 v1 0.44 Pos 0.01 Neg 1.9 Pos 1.4 Pos 
PC070 v6 0.42 Pos 0.01 Neg 1.9 Pos 1.4 Pos 
PC070 v12 0.43 Pos 0.01 Neg 1.9 Pos 1.4 Pos 
PC070 v15 0.6 Pos 0.01 Neg 1.9 Pos 1.5 Pos 
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EBNA 1 
IgG 
 Patient no 7 
        CH007 v1 0.13 Neg 0.12 Neg 1.3 Pos 1.9 Pos 
CH007 v12 0.14 Neg 0.13 Neg 1.3 Pos 1.9 Pos 
CH007 v15 0.14 Neg 0.11 Neg 1.3 Pos 1.9 Pos 
Patient no 9 
        HC 010 v1 0.28 Pos 0.06 Neg 1.8 Pos 1.7 Pos 
HC 010 v12 0.27 Pos 0.06 Neg 1.8 Pos 1.7 Pos 
HC010 v15 0.27 Pos 0.06 Neg 1.8 Pos 1.6 Pos 
Patient no 11 
        SB011 v1 0.63 Pos 0.04 Neg 0.88 Pos 1.3 Pos 
SB011 v8 0.65 Pos 0.05 Neg 0.87 Pos 1.5 Pos 
SB011 v12 0.62 Pos 0.04 Neg 0.84 Pos 1.3 Pos 
SB011 v15 0.63 Pos 0.04 Neg 0.87 Pos 1.3 Pos 
Patient no 20 
        EL020 v1 0.09 neg 0.3 neg 1.29 pos 2 pos 
EL020 v6 0.1 neg 0.28 neg 1.27 pos 2 pos 
EL020 v12 0.09 neg 0.3 neg 1.21 pos 1.86 pos 
EL020 v15 0.09 neg 0.28 neg 1.13 pos 1.84 pos 
Patient no 28 
        CD031 v1 0.31 equiv 0.05 neg 1.7 pos 1.92 pos 
CD031 v6 0.31 equiv 0.05 neg 1.72 pos 1.92 pos 
CD031 v12 0.29 equiv 0.05 neg 1.65 pos 1.9 pos 
CD031 v15 0.28 equiv 0.05 neg 1.67 pos 1.95 pos 
Patient no 31 
        JW032 v1 0.09 Neg 0.15 Neg 1.45 Pos 1.98 Pos 
JW032 v6 0.09 Neg 0.16 Neg 1.5 Pos 1.95 Pos 
JW032 v12 0.09 Neg 0.14 Neg 1.48 Pos 1.91 Pos 
JW032 v15 0.07 Neg 0.14 Neg 1.37 Pos 1.95 Pos 
Patient no 34 
        HT034 scr 0.13 neg 0.07 neg 1.64 pos 2.08 pos 
HT034 v6 0.12 neg 0.08 neg 1.73 pos 2.04 pos 
HT034 v8 0.11 neg 0.07 neg 1.71 pos 2.13 pos 
HT034 v10 0.1 neg 0.06 neg 1.72 pos 2 pos 
HT034 v13 0.09 neg 0.06 neg 1.66 pos 1.97 pos 
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 HT034 v15 0.1 neg 0.06 neg 1.64 pos 1.97 pos 
Patient no 35 
        MJ035 scr 0.22 equiv 0.26  neg 1.32 pos 1.53 pos 
MJ035 v2 0.26 equiv 0.06 neg 1.38 pos 1.53 pos 
MJ035 v6 0.26 equiv 0.04 neg 1.34 pos 1.59 pos 
MJ035 v8 0.27 equiv 0.04 neg 1.36 pos 1.57 pos 
MJ035 v10 0.25 equiv 0.04 neg 1.3 pos 1.55 pos 
MJ035 v13 0.1 equiv 0.04 neg 1.39 pos 1.59 pos 
MJ035 v15 0.25 equiv 0.03 neg 1.45 pos 1.65 pos 
Patient no 38 
        KE038 v1 0.78 Pos 0.1 Neg  1.93 Pos 1.55 Pos 
KE038 v6 0.75 Pos 0.12 Neg 1.98 Pos 1.56 Pos 
KE038 v12 0.88 Pos 0.14 Neg 2 Pos 1.48 Pos 
KE038 v15 0.91 Pos 0.14 Neg 2 Pos 1.56 Pos 
Patient no 40 
        JH040 v1 0.4 Pos 0.12 Neg 1.31 Pos 1.72 Pos 
JH040 v6 0.35 Pos 0.11 Neg 1.31 Pos 1.63 Pos 
JH040 v12 0.34 Pos 0.11 Neg 1.24 Pos 1.59 Pos 
JH040 v15 0.37 Pos 0.14 Neg 1.2 Pos 1.44 Pos 
Patient no 44 
        AH044 v1 0.08 Neg 0.03 Neg 1.56 Pos 1.74 Pos 
AH044 v6 0.08 Neg 0.03 Neg 1.6 Pos 1.76 Pos 
AH044 v12 0.07 Neg 0.03 Neg 1.62 Pos 1.8 Pos 
AH044 v15 0.07 Neg 0.03 Neg 1.54 Pos 1.74 Pos 
Patient no 45 
        SW47 scr 0.39 Pos 0.07 neg 1.37 pos 1.87 pos 
SW47 v6 0.34 Pos 0.07 neg 1.23 pos 1.92 pos 
SW47 v8 0.74 Pos 0.17 neg 1.76 pos 1.81 pos 
SW47 v10 0.63 Pos 0.08 neg 1.27 pos 1.96 pos 
SW47 v12 0.38 Pos 0.08 neg 1.34 pos 1.99 pos 
SW47 v13 0.4 Pos 0.08 neg 1.44 pos 2.1 pos 
SW47 v15 0.4 Pos 0.08 neg 1.37 pos 1.99 pos 
SW47 v8 rep 0.74 Pos 0.16 neg 1.78 pos 1.88 pos 
Patient no 48 
        LD050 v1 0.45 Pos 0.8 Pos 1.62 Pos 1.97 Pos 
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 LD050 v6 0.44 Pos 0.87 Pos 1.66 Pos 1.95 Pos 
LD050 v12 0.44 Pos 0.79 Pos 1.65 Pos 1.96 Pos 
LD050 v15 0.44 Pos 0.91 Pos 1.71 Pos 2 Pos 
Patient no 49 
        AJ048 v1 0.09 Neg 0.12 Neg 1.78 Pos 1.69 Pos 
AJ048 v6 0.08 Neg 0.12 Neg 1.84 Pos 1.61 Pos 
AJ048 v12 0.09 Neg 0.12 Neg 1.93 Pos 1.67 Pos 
AJ048 v15 0.09 Neg 0.12 Neg 1.94 Pos 1.68 Pos 
Patient no 50 
        JP049 v1 0.09 Neg 0.07 Neg 2 Pos 1.76 Pos 
JP049 v6 0.15 Neg 0.08 Neg 1.98 Pos 1.76 Pos 
JP049 v12 0.17 Neg 0.07 Neg 1.93 Pos 1.74 Pos 
JP049 v15 0.13 Neg 0.07 Neg 1.86 Pos 1.73 Pos 
Patient no 52 
        PY052 v1 0.13 Neg 0.05 Neg 1.5 Pos 1.6 Pos 
PY052 v6 0.11 Neg 0.05 Neg 1.5 Pos 1.6 Pos 
PY052 v12 0.09 Neg 0.04 Neg 1.5 Pos 1.6 Pos 
PY052 v15 0.11 Neg 0.05 Neg 1.6 Pos 1.6 Pos 
Patient no 54 
        JM054 scr 1.15 Pos  0.03 neg 1.89 pos 1.92 pos 
JM054 v2 1.14 Pos  0.03 neg 1.84 pos 1.89 pos 
JM054 v5 1.1 Pos  0.04 neg 1.8 pos 1.85 pos 
JM054 v6 1 Pos  0.03 neg 1.78 pos 1.86 pos 
JM054 v8 1 Pos  0.04 neg 1.81 pos 1.88 pos 
JM054 v10 1 Pos  0.04 neg 1.8 pos 1.92 pos 
JM054 v12 1 Pos  0.04 neg 1.81 pos 1.87 pos 
JM054 v13 1.1 Pos  0.05 neg 1.86 pos 2.04 pos 
JM054 v15 1.1 Pos  0.05 neg 1.89 pos 1.97 pos 
Patient no 56 
        JW056 v1 0.28 Pos 0.1 Neg 1.4 Pos 0.83 Pos 
JW056 v6 0.29 Pos 0.11 Neg 1.5 Pos 0.93 Pos 
JW056 v12 0.28 Pos 0.13 Neg 1.5 Pos 0.83 Pos 
JW056 v15 0.31 Pos 0.12 Neg 1.4 Pos 0.99 Pos 
Patient no 59 
        VM 58 v1 0.12 neg 0.04 neg 2 pos 1.94 pos 
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 VM 58 v5 0.11 neg 0.04 neg 2 pos 1.96 pos 
VM 58 v6 0.1 neg 0.04 neg 1.94 pos 1.9 pos 
VM 58 v8 0.087 neg 0.04 neg 1.83 pos 1.83 pos 
VM 58 v10 0.084 neg 0.04 neg 1.83 pos 1.82 pos 
VM 58 v12 0.097 neg 0.037 neg 1.8 pos 1.75 pos 
VM 58 v13 0.088 neg 0.034 neg 1.82 pos 1.79 pos 
VM 58 v15 0.078 neg 0.032 neg 1.81 pos 1.78 pos 
Patient no 60 
        BY061 v1 0.4 Pos 0.03 Neg 1.8 Pos 1.9 Pos 
BY061 v6 0.41 Pos 0.03 Neg 1.8 Pos 1.9 Pos 
BY061 v12 0.37 Pos 0.02 Neg 1.8 Pos 1.9 Pos 
BY061 v15 0.37 Pos 0.04 Neg 1.8 Pos 1.9 Pos 
Patient no 61 
        PH062 v1 0.08 Neg 0.02 Neg 0.83 Pos 1.6 Pos 
PH062 v6 0.08 Neg 0.02 Neg 0.87 Pos 1.7 Pos 
PH062 v12 0.08 Neg 0.02 Neg 0.86 Pos 1.7 Pos 
PH062 v15 0.07 Neg 0.02 Neg 0.89 Pos 1.7 Pos 
Patient no 62 
        JB063 v1 0.21 Equiv 0.11 Neg 1.4 Pos 1.8 Pos 
JB063 v6 0.2 Equiv 0.11 Neg 1.4 Pos 1.8 Pos 
JB063 v12 0.21 Equiv 0.09 Neg 1.4 Pos 1.9 Pos 
JB063 v15 0.21 Equiv 0.09 Neg 1.4 Pos 1.9 Pos 
Patient no 69 
        KS069 v1 0.13 neg 0.09 neg 1.3 pos 1 pos 
KS069 v5 0.13 neg 0.08 neg 1.27 pos 1 pos 
KS069 v6 0.12 neg 0.08 neg 1.27 pos 1 pos 
KS069 v8 0.13 neg 0.07 neg 1.28 pos 1.2 pos 
KS069 v10 0.19 equiv 0.08 neg 1.26 pos 1.2 pos 
KS069 v13 0.23 equiv 0.077 neg 1.41 pos 1.3 pos 
KS069 v15 0.18 equiv 0.078 neg 1.3 pos 1.2 pos 
Patient no 71 
        WH072 v1 0.13 Neg 0.04 Neg 0.81 Pos 1.5 Pos 
WH072 v6 0.11 Neg 0.04 Neg 0.83 Pos 1.5 Pos 
WH072 v12 0.11 Neg 0.04 Neg 0.93 Pos 1.5 Pos 
WH072 v15 0.11 Neg 0.04 Neg 0.88 Pos 1.6 Pos 
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 Patient no 72 
        JW071 v1 0.22 Pos 0.05 Neg 1 Pos 1.3 Pos 
JW071 v6 0.22 Pos 0.06 Neg 1.1 Pos 1.3 Pos 
JW071 v12 0.2 Pos 0.06 Neg 1.1 Pos 1.3 Pos 
JW071 v15 0.24 Pos 0.05 Neg 1.2 Pos 1.3 Pos 
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